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Abstract  
Diabetes and cancer are major health problems because of their high incidences 
worldwide. A growing body of epidemiological evidence indicats a molecular link between 
diabetes and breast cancer. Patients with diabetes mellitus have an increased likelihood of 
developing various types of cancers including breast cancer through the formation of 
advanced glycation endproducts (AGEs) which lead to cellular and bio-molecular 
dysfunction. However, the effects of AGEs have been poorly investigated on breast cancer 
cells. This current study examined for the first time the biological effects of various 
concentrations of BSA-derived AGEs on the invasive and hormone–independent breast 
cancer cell line MDA-MB-231 and on non- invasive hormone-dependent human breast 
cancer cell line MCF-7. 
 
Bovine serum albumin was glycated-using methylglyoxal for three days. Crosslinked 
AGEs were assessed using sodium dodecyl sulphate polyacrylamide gel electrophoresis 
followed by Coomassie blue staining. Different assays including cell proliferation, 
migration and invasion through the Matrigel
TM
 with assessment of matrix 
metalloproteinase (MMP) activity by using Zymogaraphy were performed to investigate 
the effect of different concentrations of BSA-AGE on both cell lines in vitro. Furthermore, 
signalling pathways were investigated by Western blotting and using kinexus
TM
 phspho-
protein microarray. The expression of the main receptor for AGEs (RAGE) involved on the 
MDA-MB231 and MCF-7 breast cancer cell lines was assessed by Western blotting and 
Calibur Flow Cytometer System.  
 
The results of this study demonstrated that BSA-AGEs increased MDA-MB-cell, 
proliferation, migration and invasion through the Matrigel
TM
 associated with an 
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enhancement of matrix metalloproteinase (MMP)-9 activities, in a dose-dependent manner, 
up-regulated the expression of the receptor for AGEs (RAGE) and of the key signalling 
protein, phospho-extracellular-signal regulated kinase (p-ERK)-1/2. In addition, the 
blockade of BSA-AGE/RAGE interactions using anti-neutralizing RAGE antibody reduced 
the expression of p-ERK1/2. Furthermore, in BSA-AGE-treated cells, phospho-protein 
micro-array analysis revealed the main enhancement of the over-phosphorylation of 
(ERK1/2), (p70S6K1), (STAT)-3 and (MAPK) p38, involved in cell survival, cell growth 
cell cycle and protein synthesis. In contrast, MCF-7 showed stimulatory effects of BSA-
AGEs, on cell proliferation and migration, as compared to non-modified BSA. However, 
BSA-AGEs did not change the weak invasive capacity of MCF-7 cells to cross a 
reconstituted basement membrane. In addition, BSA-AGEs induced over-phosphorylation 
of RAGE in MCF-7 cells. The investigation of signalling pathways suggests that BSA-
AGEs might contribute to breast cancer development through activation of MAPK 
pathway and activation of CREB1 transcription factor in MCF-7 cells. Throughout the 
study, the non-modified BSA had a negligible effect. In conclusion, BSA-AGEs might 
contribute to breast cancer development and progression of breast cancer. In addition, the 
up-regulation of RAGE and key phosphor-protein signalling expression induced by BSA-
AGEs might be a promising target for therapy to prevent the development of breast cancer 
in diabetic patients.  
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Chapter 1
1 
 
Chapter 1. General Introduction 
1.1 Diabetes Mellitus 
Diabetes mellitus (DM) is a group of metabolic disorders that include, hyperglycaemia, 
dyslipidaemia and obesity characterised by increased blood glucose levels. 
Hyperglycaemia is the hallmark of DM and believed to be the crucial factor in the 
development of diabetic complications. DM is a common chronic health problem that 
affects people around the world (American Diabetes Association, 2006; Biessels et al, 
2002). Long-term exposure to hyperglycaemia leads to chronic complications. For 
instance, the development of macrovascular complications includes atherosclerosis, 
cardiovascular diseases or microvascular complication that leads to retinopathy, 
nephropathy and neuropathy. Moreover, high blood glucose may lead to other diseases for 
example, depression and dementia (Biessels et al, 2002). 
The National Diabetes Statistics estimates that diabetes was the seventh leading cause of 
death in the US in 2007, due to development of diabetic complications that lead to 
morbidity and mortality (National Diabetes Statistics, 2011; National Diabetes, 2011). The 
prevalence of diabetes has significantly increased since the last decade, whereby the World 
Health Organization (WHO) estimates that people with diabetes are expected to increase 
between 2000 and 2030 from 285 million to 439 million (Shwa et al, 2010). In addition, in 
2011, the average prevalence of diabetes in adult population in the UK was 4.45% 
(Diabetes UK, 2012).  
The National Diabetes Data Group (NDDG) and the WHO have recognized four types of 
diabetes (American Diabetes Association, 1979; Harris, 1998). The two major types that 
usually occur are Type 1 and Type 2. Type 1 DM, or insulin-dependent DM (IDDM), is 
usually a consequence of autoimmune failure that leads to the destruction of the pancreatic 
β-cells. This leads to the inhibition of insulin production, which counts for approximately 
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10% of all diabetic cases. Furthermore, Type 1 diabetes usually develops in early age 
(often before the age of 40) and the patients require regular insulin injections for life. 
However, Type 2 diabetes or non-insulin–dependent DM (NIDDM) is a multifactorial 
disease. Generally, this type is more common and counts for 90% of all diabetic cases. 
Type 2 diabetes leads to the production of inadequate levels of insulin or production of 
insulin that cannot functional correctly due to insulin resistance (Rolo and Palmeira, 2006). 
Third type of diabetes known as gestational (GDM) occurs spontaneously during 
pregnancy and could lead to development of Type 2 diabetes. GDM is caused by many 
factors such as hormonal changes, environmental factors and family history (Kuzuya et al, 
2002). Fourth type of diabetes is classified under other specific types of diabetes mellitus 
(Table 1.1) (Maraschin, 2012). 
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Table 1.1: Diabetes mellitus classification 
1. Type 1 Diabetes 
2. Type 2 Diabetes 
3. Gestational Diabetes 
4. Other types 
Genetic defects of B cell function (MODY, Mitochondrial) 
Genetic defects in insulin action 
Diseases of exocrine pancreas 
Endocrinopathies 
Drug or chemical induced 
Infections 
Uncommon forms of immune mediated diabetes 
Other genetic syndromes (Down, Turner, other) 
 
1.1.1 Causes of Diabetes  
Specific etiology of diabetes is not defined, but there are numerous studies investigating 
the causes of diabetes, however it remains unclear what causes lead to the particular type 
of diabetes. Scientists have proposed the causes of DM to be environmental factors, 
obesity, genetic susceptibility, viral infection and autoimmune diseases (Notkins and 
Lernmark, 2001: Hossain et al, 2007). It is common consensus that genetic and 
environmental factors play a significant role. The mechanism of Type 1 DM consists of 
severely deficient insulin production due to destruction of islets cells within the pancreas 
(Bresson and Herrath, 2004). Insulin is a protein hormone produced by pancreatic islets 
cells of Langerhans (β-cells) with its secretion induced by increased blood sugar levels 
after meals and incretion (a group of gastro-intestinal hormones). Insulin act on receptors 
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virtually present on all body cells but highly concentrated in liver, muscles and adipose 
tissue. Stimulated insulin receptors act on glucose transport protein-4 (Glut-4) which gets 
translocated from cytoplasm to cell membrane allowing glucose to move from blood to 
inside the cell. Eventually glucose is metabolised to generate energy in the form of ATP or 
gets stored as glycogen in adipose cells to form triacylglycerol. According to the type of 
diabetes, different pathological processes are involved. Inheritance play a significant role 
in Type 1 DM and its clinical development is triggered by a viral infection, probably being 
coxsackie B4 virus, which destroy pancreatic cells. Furthermore, it has been suggested that 
Type 1 DM is an autoimmune response caused by a virus where the immune system 
attacks both virally infected and pancreatic beta cells (Fairweather and Rose, 2007). While, 
a cause of Type 2 DM is less defined but is commonly associated with different risk factors 
such as, obesity, age, gender, lifestyle and genetic make up. Some of these factors can be 
controlled (such as obesity), while others are uncontrollable such as age, genetics and 
gender. Obesity leads to the reduction of insulin receptors found on the cell membrane, 
thus preventing the muscle from using insulin sufficiently. Genetic factors may include 
family history of insulin resistance or genetic mutation (American Diabetes Association, 
2010). 
 
1.2 Hyperglycaemia and Diabetic Complications  
Hyperglycaemia or high blood glucose is characterised by the presence of excessive 
amount of glucose that circulate in the blood. Numerous studies suggest that exposure to 
chronic hyperglycaemia plays a major role in the pathogenesis of diabetic complications 
and many chronic diseases. (American Diabetes Association, 2009; Biessels et al., 2002). 
Notably, the concentration of glucose must excel above 11.1 mmol/l (UK units) or 200 
mg/dl (USA units), but the symptoms are not recognised until the glucose value reaches 
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15-20 mmol/l (250-300 mg/dl) (Grundy, 2012). Pre-hyperglycaemia or pre-diabetes is the 
same condition described which was also classified by different health organizations at 
different periods. Moreover, pre-hyperglycaemia, which include impaired fasting glucose 
and impaired glucose tolerance could lead to the development of Type 2 DM, stroke and 
heart disease. Hyperglycaemia can cause alterations at the cellular level and increase the 
level of oxidative stress that promotes pro-inflammatory responses which leads to 
atherosclerosis and other diabetic complications (Fowler, 2008). Moreover, 
hyperglycaemia also leads to the formation of metabolic and haemodynamic derangement, 
which is considered to play an important role in vascular diabetic complications (Aronson, 
2003; Wautier and Guillausseau, 2001). Chronic hyperglycaemia inflicts damaging effects 
on tissues through various biochemical mechanisms leading to the development of diabetic 
complications (Brownlee, 2001). Other causes that lead to hyperglycaemia, include 
medication, serious illness, physiological stress and endocrine diseases (Srinivasan, 2012). 
The particular role of hyperglycaemia in the molecular or cellular basis of long-term 
complications remains unclear and therefore needs further investigation. However, several 
theories have been devised, particularly one that has received considerable interest, is the 
role of protein glycation (Ahmed, 2005).  
 
1.2.1 Metabolic Pathways of Hyperglycaemia 
The biochemical pathways between chronic hyperglycaemia and tissue damage are not 
completely understood. Several studies suggest a relation between hyperglycaemia and 
diabetic complications induced through several mechanisms. These mechanisms include 
hyperactivity of the polyol pathway (Chung and Chung, 2005), increased polyol pathway 
flux through biosynthesis in hexosamine pathway (Fulop et al., 2007), activation of protein 
kinase C (PKC) (Das Evcimen and King, 2007) and glycation of proteins and lipids (Goh 
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and Cooper, 2008). Other studies have suggested that there is an alternative mechanism 
involved where the mitochondrial electronic transport generates an overproduction of 
superoxide (Brownlee 2001; Nishikawa et al., 2000). However, glycation or protein 
glycation are known to be a major factor in long-term diabetic complications. 
                                  
1.2.1.1 Glycation 
One of main consequence of increased hyperglycaemia is the increasing interaction of 
glucose with proteins, which is called glycation. Glycation is generally accompanied by 
oxidation reactions. In the presence of molecular oxygen, and under conditions of 
enhanced metal-catalysed glycoxidation, protein dicarbonyl compounds are produced from 
Amadori products via a protein enediol generating free radicals.This radical reduces 
molecular oxygen to simultaneously generate oxidation. This consequence has a main role 
in damaging important biomolecules, such as lipids, proteins and nucleic acids (Baynes 
and Thorpe, 1999). The best examples of glycation are pentosidine and 
Carboxymethyllysine (CML) (Basta et al., 2004). Glycation contributes to the 
development of diabetic nephropathy and other microvascular diseases (Ahmed, 2005). 
Furthermore, glycation affects the glomerular basement membrane and extracellular matrix 
molecules that change the level of soluble signals, such as cytokines, hormones and free 
radicals (Wautier and Guillausseau, 2001). 
 
1.2.1.2 Hexosamine Biosynthesis Pathway  
Commonly, when cells containing high volumes of glucose molecules will readily undergo 
glycolysis due to the excess volume of glucose-6-phosphate. However, the intermediate 
product (fructose-6 phosphate) of glycolysis may divert to signalling pathway. This leads 
to the production of glucosamine-6 phosphate and then uridine diphosphate N-
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acetylglucosamine by glutamine fructose-6 phosphate amidotransferase (GFAT). The N-
acetylglucosamine binds to the serine and/or threonine residues transcription messenger. 
This process is similar to phosphorylation and modification of N-acetylglucosamine may 
cause the gene expression to change. Cells under hyperglycaemic conditions will lead to 
increased flux in the hexosamine biosynthesis pathway that causes damage to blood vessels 
by increased expression of growth factor-β1 andpalsminogen activator inhihibitor-1 (Folli 
et al., 2011).    
 
1.2.1.3 PKC Activation 
During hyperglycaemia, there is an overproduction of diacylglycerol (DAG) by the cell. 
DAG is a critical cofactor for protein kinase C (PKC) that induces several growth factors 
(Srivastava, 2002). Increased levels of PKC have an effect on gene expression, smooth 
muscle cells and vascular wall (Aronson and Rayfield, 2002). Moreover, PKC activation 
results in abnormalities in the capillary membrane by increasing the thickness of their 
basement and is the primary defect observed in vascular complications (Cade, 2008).      
  
1.2.1.4 Polyol Pathway  
High concentration of glucose within the cell is reduced to sorbitol and oxidised to 
fructose, this is called polyol or sorbitol-alose reductase pathway. Thus, the reaction causes 
increase consumption of the co-factor of aldose reductase nicotinic acid adenine 
dinucleotide phosphate (NADPH). NADPH is a vital molecule for the production of a 
critical intracellular antioxidant by reducing glutathione. The lower levels of reduced 
glutathione make the cell more susceptible to oxidative stress (Giacco and Brownlee, 
2010). Moreover, high levels of glucose through the polyol pathway causes tissue damage 
of the lens, kidney and peripheral nerves (Chung et al., 2003). 
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1.2.1.5 Mitochondrial Superoxide Production 
Mitochondria are effective producers of cellular superoxide. However, the overproduction 
of superoxide by mitochondria leads to damage of molecules such as, lipids, proteins and 
nucleic acids. Mitochondrial role is particularly prone to oxidative damage, leading to 
decreased mitochondrial ATP synthesis, cellular calcium dyshomeostasis, and change of the 
mitochondrial permeability transition, all of which predispose cells to apoptosis or necrosis 
(Brownlee, 2004). Hyperglycaemia leads to the inhibition of the activity of the glycolytic 
enzyme (glyceraldehyde-3-phosphate dehydrogenase) contained within the mitochondria 
and this result in excessive superoxide production. Furthermore, superoxide species are 
considered to play an important role in activating different pathways implicated in diabetic 
complications such as, PKC, polyol and hexosamine pathway through glyceraldehye 3-
phosphate (Sharma et al., 2002; Coughlan et al., 2008).  
 
1.3 Maillard Reaction 
The discovery that sugars can react with proteins was made by a French scientist called 
Louis-Camille Maillard who was the first one observe a colour change in food from yellow 
to brown upon heating (Maillard, 1912). This was due to the endogenous reaction between 
the carbonyl group of a reducing sugar with an amino group of protein or other 
macromolecules (lipids and nucleic acids). This is reaction known as “Maillard reaction”, 
which has attracted a great deal of attention amongst researchers in the medical field to try 
understand the physiological and pathological consequences of protein glycation in 
biological systems (Nagai et al, 2012; Gerrard, 2006).  
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1.4 Chemistry of Protein Glycation 
Protein glycation is a spontaneous reaction that occurs over a period of hours, days, 
months, and depends on the duration and severity of the glycaemia (Ahmed, 2005). 
Glycation reaction is subdivided into three stages, which result in various protein-protein 
cross-linked and non-crosslinked AGEs .A general pattern of the chemistry involved in the 
glycation reaction is outlined in Figure 1.1.  
 
1.4.1 Protein Glycation: Early Stage 
 In 1953, Hodge proposed an early stage reaction that is initiated by the addition reaction 
between carbonyl groups on reducing sugars (i.e. glucose or fructose) and amino groups, 
on proteins (i.e. lysine or arginine) forming a Schiff base. Schiff base is formation rapid 
and reversible that occuring within a few hours (Hodge, 1953; Monnier et al., 1981).  
 
1.4.2 Protein Glycation:  Intermediate Stage 
Intermediate  stage, which results from the Schiff base that rearrange giving product called 
Amadori. Amadori product undergoes further reactions to give highly reactive products 
such as glyoxal and methylglyoxal through a series of chemical rearrangements, oxidation 
and dehydration reactions (Thornalley, 2005). 
 
1.4.3 Protein Glycation:  Advanced Stage 
Glycated protein can undergo further series of repeated dehydrations, condensations, 
fragmentations, oxidations and cyclisation reactions involving dicarbonyl intermediates, 
leading to stable and irreversible extremely heterogeneous group of compounds called 
advanced glycation endproducts (Ahmed, 2005; Schleicher et al., 2001; Yim et al., 2001). 
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Figure 1.1: Schematic representation of the reaction of advanced glycation endproduct, 
where R1 and R2 represent different carbon alkyl chain (Aronson and Rayfield, 2002). 
 
1.5 Characterisation of AGE 
AGEs are complex molecules that have the ability to generate fluorescence and crosslinks 
between proteins. The role of AGEs has been extensively studied but their mechanism of 
formation is not fully understood (Bousova et al., 2005). Although many structures of 
AGEs have been identified in vitro, and vivo, AGE-structures are classified into four 
groups: 
1.5.1 Fluorescent Crosslinking AGEs 
There are minute amounts of AGEs 1% or less that are able to generate fluorescence when 
they crosslink with protein (Dyer et al., 1991). For instance, when arginines reacts with 
lysine then produce pentosidine, which reacts with several carbohydrates to generate 
fluorescence and are detected in a variety of tissues, such as kidney, lung, liver, skin and 
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blood proteins. Pentosidine is a best example of a fluorescent crosslinking AGE and 
commonly used as a biomarker, another example is crossline (Salman et al., 2009).  
 
1.5.2 Fluorescent Non Crosslinking AGEs 
Methylglyoxal can also produce a fluorescent non cross-linker of AGEs when it reacts with 
N-α-t-butoxycarbonyl-L-arginine, such as argpyrimidine. Moreover, this fluorescent 
product can develop and increase with age and diseases (Shipanova et al., 1997).    
 
1.5.3 Non-Fluorescent Crosslinking AGEs 
The non-fluorescent cross-linkers are major structures that maybe detected by ELISA (Goh 
and Cooper, 2008). The best examples of a crosslinked AGE are glyoxal lysine dimer 
(GOLD) and methylglyoxal-lysine dimer (MOLD), which are believed to be highly 
reactive.  
 
1.5.4 Non-Fluorescent Non Crosslinking AGEs 
N-carboxymethyllysin (CML) is a non-fluorescent non cross-linked AGE that is utilised as 
a marker for oxidative stress (Linton et al., 2001). This is formed during the metal-
catalysed oxidation conditions in the presence of protein, and believed to contribute to 
pathological effects in complications of diabetes such as retinopathy and nephropathy. 
 
1.6 Advanced Glycation Endproducts 
AGEs may alter the extracellular matrix (ECM), cytokines and change the action of 
hormones through engagement of cell surface receptors, and which generate oxidative 
stress and have been implicated in the pathogenesis of diabetic complications. For instance, 
damaging and changing tissue structures, these alterations are accompanied by thickening 
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of the capillary basement membrane, increased permeability of capillaries, reducing the 
vessel walls, loss of pericytes and increased endothelial cell turnover. The formation of 
AGEs is via different pathways, one of which causes crosslink that lead to dysfunctions at 
the intracellular level. Alternatively, AGEs trigger many growth factors, chemokines, and 
cytokines and induce oxidative stress and free radicals, which cause aggregations of 
different molecules, such as proteins and lipids (Vlassara and Palace, 2002). AGEs form 
gradually and accumulate with time. Although, glucose is a major precursor of AGE 
formation, recent studies indicate that other reducing sugars such as methylglyoxal (MG), 
glyoxal and α-oxoaldehydes are considered more effective and reactive than glucose 
(Vander and Hunsaker, 2003; Singh et al., 2001).  
 
1.6.1 AGE Formation via Methylglyoxal or other Carbohydrates  
Many carbohydrates can react with amino groups when they undergo the glycation 
reaction, while some reactions may also involve an oxidation process through the 
glycoxydation reactions. For instance, it is possible for the glucose molecules to readily 
react with amino groups under non-oxidative pathways to produce pyrraline or pentosidine 
and N6-carboxymethyllysine (CML) under oxidative pathway. MG is a reactive dicarbonyl 
compound (Figure 1.2) that is thought to contribute to the intracellular formation of AGEs, 
and in turn induces cellular oxidative stress and up regulation of cell adhesion molecules 
(Shipanova et al, 1997). This is due to its numerous origins causing it to be readily 
available during hyperglycaemia and other in vivo conditions. Furthermore, the three main 
factors that form MG are triosephosphate degradation, lipid peroxidation and side reactions 
caused by glucose-mediated glycation (Uchida et al., 1997; Lv et al., 2011). MG increases 
the level of superoxide species that can quench nitric oxide and cause cellular damage to 
the DNA, proteins, endothelial cells or neutrophils (Shinohara et al, 1998). Moreover, MG 
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commonly reacts with amino acids (such as lysine, arginine and cysteine residues) (Grillo 
and Colombatto, 2008). Increased levels of MG have been detected in the cells of patients 
with Type 1 and Type 2 diabetes such as mesangial cells and, red blood cells. Furthermore, 
it is associated with other diabetic complications such as microvascular disease and 
atherosclerosis (Karachalias et al., 2003). More specifically, MG ultimately causes either 
reversible or irreversible protein modification. Notably, this is more likely to occur in the 
red blood cell, kidney and lens. A previous in vivo study under physiological conditions 
found that the maximum concentration of MG in a diabetic patient was 2.4 µM; and this 
level was sufficient in irreversibly changing plasma proteins (Lo et al., 1994).  
 
 
 
 
 
 
Figure 1.2: Methylglyoxal molecular structure (left hand side) and 3D structure (right 
hand side) is a compound that can cause glycation. 
 
 
1.7 Intracellular Glycation and AGE Formation 
It is now apparent that intracellular AGE formation is the key source of both intra- and 
extracellular AGE. During of hyperglycaemia a significant rise in concentration of 
intracellular sugars occurs therefore, the main sources of AGEs are derived from reactive 
metabolic intermediates. AGEs are formed from different carbohydrate such as, 
methylglycoxal, ascorbate, and glucose. Moreover, most intracellular precursors of AGEs 
such as, glyoxal, methylglyoxal and 3-deoxyglucosones, are particularly reactive due to the 
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presence of two carbonyl groups, as well as their high reactivity with arginine residues on 
proteins (Shinohara et al., 1998; Thornalley, 1999). Furthermore, some other compounds 
containing free amino groups, including adenine and guanine bases in DNA are also prone 
to glycation and AGE formation, probably by reactive intracellular sugars. AGEs could 
also form on phospholipid and induce lipid peroxidation by a direct reaction between 
glucose and amino groups on phospholipids such as phosphatidylserine residue, which are 
important precursor for the glycation reaction (Ahmed, 2005; Mironova et al., 2001). 
 
1.7.1 Exogenous Source of AGEs  
Despite the fact that there are different types of AGEs formed intracellularly from glucose 
and fatty acid oxidation, several studies confirm that AGEs are also derived from an 
exogenous source (Giacco and Brownlee, 2010). Exogenous sources have significant effect 
on biological systems and increase the risk of diabetic complications and other diseases 
(Peppa et al., 2003; Vlassara and Palace, 2002). The common exogenous sources that 
generate AGEs are tabacco smoking and diet. Tabacco or cigarette smoke have high 
concentrations of specifiic components such as methylglyoxal that react with plasma and 
generate different adducts of AGEs. Moreover, high level of AGEs have been observed in 
the serum of smokers compared with non-smokers (Nicholl et al., 1998). Diet or food have 
been shown as another source of  highly reactive AGEs. However, the amount,  type of 
diet such as protiens, heat processing and duration of processing time are factors that 
influences the formation of AGEs (Goldberg et al., 2004; Negrean et al., 2007). These 
AGEs have been implicated in vascular disease and ageing (Nicholl et al., 1998: Vlassara 
et al., 2008).  
 
15 
 
1.8 Biological Effects of AGEs 
Increasing evidence demonstrated that AGEs could have influence on the function of 
biological systems and cause damage to most tissues. First, by their modification of protein 
can alter cellular structure, enzymatic activity, and biological half-life, inhibit specific 
function of proteins, and cause damage to plasma proteins and lipoproteins. Secondly, via 
the interaction between AGEs and RAGE they can increase oxidant stress and induce a 
cascade of inflammatory reactions. The reactivity between the sugars and amino groups is 
dependent on the modified protein, where some modifications render a more reactive 
amino group (Sharma et al., 2002). This in turn has a serious impact on the cells during 
their life. Additionally, the formation of AGEs may increase oxidative stress in some 
molecules as compared to others. In addition, some modified proteins within the cell, for 
example, HSC-70 protein found within stem cells is known as the most modified protein 
(Hernebring et al., 2006). 
 
The increased glycation and accumulation of tissue AGEs may contribute to the 
pathophysiology of diabetic complications. However, extracellular matrix proteins (EMP) 
contribute to the functions of the cell and basement membrane as it contains a wide array 
of growth factors. These growth factors play an important role in the synthesis of the cell 
and nucleus. The AGE accumulation causes the disruption of the matrix proteins and 
matrix-cell elements. However, this process may also affect and inhibit important 
molecules in the cell matrix this accumulation of AGE has the ability to change cellular 
adhesion thus, influencing the ability of cellular binding and moleculor charge leading to 
changes in cell-collagen interaction causing alteration of collagen (Basta et al, 2004). 
Karmakar and his college (2012) suggested that advanced glycation endproducts may 
cause tissue damage through several mechanisms include: modified intracellular proteins, 
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modified extracellular matrix proteins and by modified plasma proteins that interact with 
AGE-RAGE (Karmakar et al., 2012). In addition, AGE accumulation on vascular ECM 
results in increased stiffness and decreased vascular elasticity (Smit and Lutgers, 2004; 
Tan et al., 2002). 
The modification of the proteins has a critical effect on the intracellular proteins by 
changing their properties. However, this depends on the formation of AGEs and the 
presence of sugars like fructose or glucose. Furthermore, it is believed that the intracellular 
accumulation of AGEs may affect the activation of signalling pathways in the cells and 
cause alteration of vital proteins and enzymes. In addition, the intracellular AGEs cause 
changes to the mitochondrial proteins and leads to critical DNA damage (Ahmed, 2005).  
 
1.9 Advanced Glycation Endproduct Receptors 
Advanced glycation endproducts have non-specific cellular receptors, which belong to the 
immunoglobulin super-family of cell surface molecules (Hudson and Schmidt, 2004). The 
interaction that AGEs has with its receptors plays a significant role in diabetic 
complications. The first description of this receptor for advanced glycation endproducts 
(RAGE) was in 1992 (Neeper et al, 1992). RAGE consists of a single hydrophobic 
transmembrane helix, short highly charged cytoplasmic tail and an extracellular site. The 
extracellular region of RAGE is composed of three immunoglobulin-like domains, one V-
type and two C-types. The V-type domain allows for ligand binding to occur, where there 
are interaction between RAGE and the extracellular ligands (Schmidt  et al., 1992). RAGE 
is anchored by a fourth transmembrane domain that is connected to a fifth intracellular 
domain. This fifth domain is highly charged that allows for the interaction between the 
domain and cytosolic transducer molecules to facilitate, as demonstrated in Figure 1.3 
(Ahmed, 2005). RAGE behaves as signal transducer receptor for AGEs, in particularly for 
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CML as this is the most common type of AGE found in vivo. Other known receptors of 
AGEs are oligosaccharyl transferase-48, macrophage scavenger receptor types A and B1 
(CD36), termed AGE (AGE-R1), 80K-H phosphoprotein (AGE-R2) and galectin-3 (AGE-
R3) (Kalousova et al., 2005; Ohgami et al., 2002). RAGE has the ability to trigger the 
activation of growth factors such as vascular endothelial growth factor (VEGF), which 
leads to angiogenesis and increased release of cytokines including tumour necrosis factor-α 
(TNF- α) and interleukin-1α (IL-1α) (Bierhaus et al., 2005; Ma et al., 2007). Furthermore, 
RAGE is highly expressed in a wide range of cell types such as, embryonic cells, lungs, 
macrophages, endothelial cells, epithelial cells, smooth muscle cells, astrocyte cells, renal 
mesangial cells and some malignant cells (Basta, 2008; Brett et al., 1993). Moreover, 
current studies have shown that high expression of RAGE is involved in chronic 
inflammatory conditions, vast amount of immune cells, and endothelial cells. In addition, 
RAGE interacts with a variety of ligands, such as S100/calgranulins that are expressed in 
chronic inflammation, amyloid-β peptide Mac-1 and HMGB1 (amphoterin) (Chuah et al., 
2013). RAGE is associated with invasion and metastasis in many types of cancers, for 
example colorectal cancer. AGE induce oxidative stress generation in variety of cells 
through the interaction with RAGE, which leads to the release of inflammatory response 
especially when high glucose concentrations are present. Numerous studies have reported 
that RAGE is associated with many chronic diseases as they initiate intracellular signalling 
that leads to cellular disruption by altering the proteins structure (Ahmed, 2005; Chuah, et 
al., 2013).   
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Figure 1.3: Schematic representation of the full-length of RAGE. It is composed of 
extracellular domain (one V-type domain and two C-types domains), transmembrane 
domain and intracellular tail (Chuah et al., 2013). 
 
 
1.10 Free Radicals and Oxidative Stress  
The exposure of the human body to free radicals may occur both exogenously and 
endogenously. The generation of theses free radicals may be caused by numerous factors, 
such as exposure to radiation, smoking, pollution, sunlight, alcohol and some medicines. 
The cells require oxygen for the production of energy when undergoing the process of 
mitochondrial respiration. This process results in the production of free radicals. These 
molecules are highly reactive and contain one or more unpaired electrons. Thus, this 
unstable state causes the molecules to either accept or donate electrons in order to become 
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more stable, which leads to a chain reaction where new radicals are formed and can react 
with other macromolecules. Current research has proposed that AGEs play a crucial role in 
the generation of free radicals. Whereby, AGEs leads to the overproduction of 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase that is an essential source 
of vascular oxidative stress in Type 2 DM (Tan 2007). The high level of NADPH oxidase 
activity leads to the formation of free radicals and reduction of cellular antioxidants. 
Moreover, AGEs interact with their receptors (RAGE) that modifies the enzymatic activity 
in the cells and induces free radicals. AGEs also induce the up regulation of specific genes 
through activating transcription factor NF-κB (Maritim, et al., 2003). The overproduction 
of free radical species may result from numerous sources; such as mitochondrial 
respiration, PKC-dependent activation system and RAGE-triggered cellular oxidant stress 
(Lander et al., 1997). The common free radicals that cause damage to essential 
biomolecules are oxygen-free radicals or reactive oxygen species (ROS). ROS are reactive 
molecule that contains oxygen. There are several ROS that are involved in the generation 
of oxidative stress under physiological conditions, such as superoxide (  
 ), hydroxyl 
radical (   
 ), nitric oxide radicals (   ), peroxyl radical (    ) and non-radical H2O2. 
The oxidation of glucose in diabetic patients is considered the major cause of ROS 
production in the form of reactive hydroxyl radicals. However, highly protective defence 
systems within the cell produce antioxidant that protects the cells and organs (Valko et al., 
2007). Furthermore, there are different enzymatic and non-enzymatic antioxidants present 
in the body that fight against ROS. The enzymatic defence includes catalase, glutathione, 
glutathione reductase and peroxidase; whereas, non-enzymatic antioxidants includes 
vitamin E and C, carotenoid and flavonoid (Comhair and Erzurum, 2002; Jakus, 2000). 
Oxidative stress occurs when there is an imbalance between the production of ROS and the 
ability of the biological system to detoxify using scavengers (Halliwell, 1994). This 
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imbalance may occur either because of reduced antioxidants or because of excessive free 
radical production. The disturbance in this balance may cause damage to lipids and DNA. 
The oxidative DNA damage has mutagenic and carcinogenic effects, which could 
significantly affect oncogene or tumour suppresser genes. Some studies have suggested the 
relationship between ROS and the progression of carcinogenesis. Furthermore, ROS 
potentially can cause tissue dysfunction and damage as implicated in the pathology of 
different diseases, such as inflammatory, neurodegenerative diseases, ageing and diabetes 
(Dickerson et al., 2002; Atalay and Laaksonen , 2002; Giacco and Brownlee, 2010). 
 
1.11 Diabetic Complications and Glycation 
Diabetic patients are at high risk of developing serious complications, due to high blood 
glucose levels. This includes hyperglycaemia through the production of AGEs, 
dyslipidaemia that results from the aberrations in lipid metabolism and oxidative stress. In 
addition, the intracellular interaction between AGEs and RAGE, results in inadequate 
endothelial barrier function that may ultimately accelerate atherosclerosis (Aronson and 
Rayfield, 2002). For instance, Figure 1.4 demonstrates an interaction that leads to oxidative 
stress and finally increased levels of surface procoagulant activity and monocyte adhesion. 
The two main complications strongly associated with diabetes are macrovascular and 
microvascular diseases (Ahmed and Thornalley, 2007; O'sullivan and Dinneen, 2009). 
These complications affect several systems in the body, such as the heart, kidney, eye and 
brain. Furthermore, recent studies have shown that a major long-term complication of 
diabetes maybe cancer (Coughlin et al., 2004; Giovannucci, et al., 2010). 
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Figure 1.4: The interaction of AGE and RAGE on the endothelial cell. This schematic 
explains the effect of AGE-RAGE interaction on the endothelial cell result in the 
production of oxidative stress, transcription factor NF-κB, and VCAM-1 and consequently 
reduced barrier function (Aronson and Rayfield, 2002). 
 
1.11.1 Microvascular Disease 
Many studies have revealed that microvascular disease is a common consequence of 
diabetes and depends on the severity and duration of hyperglycaemia (Peppa and Vlassara, 
2005). Moreover, there are many factors contributing to microvascular complications that 
include nephropathy, retinopathy and neuropathy, but the key factor is the accumulation of 
AGEs. The acceleration of AGEs leads to the morbidity in the final-stage of kidney failure 
and diabetic nephropathy has a 40-50% chance in all diabetic patients (Wolf, 2004). The 
accumulation of AGEs results in glomerular basement thickening and mesangial matrix 
expansion, which is responsible for the control of blood flow through the capillaries that 
leads to the reduction in renal clearance (Coughlan et al., 2005). Diabetic retinopathy is 
one of the most common complications of diabetes that leads to blindness, and 10,000 
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cases develop every year in the United States (Fowler, 2008). Many studies indicate that 
the increased level of AGEs in diabetic patient plays an important role leading to the  
2001; Chibber et al., 1997; Stitt and Curtis, 2005; Zhang et al, 2011). Diabetic neuropathy 
is a common complication of diabetes, arising in more than 50% of all diabetic patients. It 
arises because of progressive damage to the peripheral sensory and autonomic nervous 
systems (Magalhães et al., 2008). Many studies show that the formation of AGEs is 
considered as important biochemical pathways involved in diabetic neuropathy (Sugimoto 
et al., 2008; Wada and Yagihashi, 2005). Further, the interaction of AGEs and RAGE is 
involved in nerve dysfunction, which may play an inflammatory role in peripheral nerve 
damage, although their precise role remains unidentified (Huijberts et al., 2008). 
 
1.11.2 Macrovascular Disease 
Macrovascular disease is a major complication of diabetes and involves a wide range of 
pathological changes leading to functional and structural abnormalities. Macrovascular 
disease in diabetes includes an accelerated form of atherosclerosis, which is responsible for 
the high-incidence of several vascular diseases, such as, stroke, and peripheral vascular 
diseases (Laakso, 1999; Rahman et al., 2007). Atherosclerosis leads to cardiovascular 
diseases that cause 70% mortality in Type 2 diabetes (Cade, 2008). The International 
Diabetes Federation confirmed that the postprandial hyperglycaemia (after diet intake) is a 
significant risk factor of macrovascular disease (Parkin and Davidson, 2009). However, 
meta-analysis showed that hyperglycaemic control significantly reduces the risk of 
macrovascular disease. To date, several studies on animals and humans indicate that AGEs 
are involved in hyperglycaemic progression, which increase the risk of atherosclerosis 
(Jandeleit-Dahm and Cooper, 2008; Vlassara and Palace, 2002; Peppa and Vlassara, 2005).  
AGEs have deleterious effects and cause change to the structural vessel wall 
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macromolecules and other abnormalities. AGEs also causes change in endothelial 
dysfunction, and increase stiffness of the arterial wall and human aortia (Laakso, 1999; 
Fowler, 2008). Moreover, AGE when added to nitric oxide (NO) leads to blocked NO 
activity, thus generate the production of ROS, these ROS reduce the half-life of endothelial 
synthesis and function (Pandolfi and De Filippis, 2007; Goh and Cooper, 2008). Moreover, 
AGE formation is associated with a significant acceleration of atherosclerosis through 
different mechanisms, including the cross-linking of proteins, the modification of matrix 
components and abnormal lipoprotein metabolism, for example, LDL is modified by AGE 
and this LDL–AGE has been found in the serum of diabetic patients and contribute to 
reduced clearance of LDL from the body (Goh and Cooper, 2008; Ahmed, 2005).   
 
1.11.3 Other Complications Related to Glycation 
Recently, it has become clear that AGEs are involved not only in diabetic complications 
but also in a number of other diseases (Xue et al., 2011). Increased risk of hyperglycaemia 
and oxidative stress accelerate the rate of AGE formation. AGE formation is involved in 
pathophysiology of many diseases such as, Alzheimer diseases (AD), Parkinson disease 
cancer, and some types of liver disease (Hyogo and Yamagishi, 2008; Grillo and 
Colombatto, 2007). An in vivo study on normal rats has demonstrated that some model 
compounds have the ability to cause harmful effects on tissues and cause an increase in the 
level of mesangial volume that is related to neurodegenerative diseases (Vlassara et al, 
1994). Moreover, AGEs are claimed to contribute to degenerative diseases by the AGE-
RAGE up regulation and have been reported in the pathogenesis of AD. AD is 
characterised by a gradual and steady loss of memory. However, specific types of AGEs 
induce ROS that activate (NADPH) and lead to neuronal dysfunction. In addition, AGE 
accumulation increases the deposition of beta amyloid peptide (Aβ) in both plaques and 
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tangles, and is related to the progression of AD (Chuah et al., 2013; Gella and Durany, 
2009). Another complication related to AGE has been reported in certain liver disease such 
as cirrhosis through the interaction between AGE and RAGE (Semba et al., 2010). 
 
1.12 Introduction to Cancer 
Cancer is a harmful disease that is characterized by rapid production of abnormal and 
uncontrolled cell division, which leads to malignant growth. Cancer cells have the ability 
to invade surrounding tissues and possess the ability to metastasize. Cancer also may 
spread through the blood stream or lymphatic system. Cancer is considered as a major 
cause of death in the world. During 2008, it was responsible for 7.6 million deaths 
worldwide (approximately 13% of all deaths) (World Health Organization, 2008).  In UK 
396.2 people per 100,000 of the population were diagnosed with cancer in 2011 (Cancer 
research in UK).  In 2010, cancer caused the deaths of close to 1,500 Americans each day. 
Notably, it is the second most common cause of death in the US and responsible for nearly 
one in every eight deaths. The majority of cancer-related deaths each year are due to 
cancer of the breast, liver, lungs, stomach, and colon. Moreover, there is a rapid increase in 
the incidence of melanoma, prostate breast, and ovarian cancers (Ferlay et al., 2010). 
There is a difference between men and women with regard to most common types of 
cancer. Breast cancer is the most common female cancer, with approximately 1.4 million 
cases arising annually (Ferlay et al., 2010). Furthermore, 22 million deaths worldwide 
because of cancer are expected to occur in 2030 (World Health Organization, 2014). 
Cancer is caused by various external risk factors such as, chemicals, radiation, tobacco, 
immunosuppressive treatment and infectious organisms and internal risk factors such as 
inherited mutations, declines in the immune function and hormones changes (Vajdic et al., 
2006; Beghe and Balducci, 2005).  
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1.13 Pathophysiology of Cancer: 
 Healthy cells have a particular size, morphology, functionality and growth rate that 
specific to the original tissues and serve the function of that organ. While cancer cells 
differ from healthy cells in morphology, cellular size, structure, function, and growth rate. 
The Malignant cells do not have the normal controls of growth seen in normal cells, and 
grow uncontrollably (Bekher, 1992). The uncontrollable growth leads to invasion of the 
cancer cells to the adjacent normal tissues and structures or migration of cancer cells to 
distant organs. When cancer cell loses its ability to differentiate like a normal cell, it will 
lose its normal function required by normal tissues and this resulted in a variety of tissue 
alterations and malfunctions: lower immunity, cachexia, anemia, leukopenia and 
thrombocytopenia (McCance and Roberts, 1998). 
Histologically speaking, there are three characteristic features of cell abnormality. The first 
one called Dysplasia, which can be defined as cellular disorganization in terms of cell size, 
shape, or arrangement. While the second type is called Metaplasia, which is the primary 
level of dysplasia (early dysplasia). Metaplasia is a reversible process which is benign, but 
abnormal compared to healthy cells. The disorder in metaplasia results in changes of cells 
size, shape or orientation lining up, or in inappropriate or faulty tissue behaviors (McCance 
and Roberts, 1998). Anaplasia is complete absence of cellular differentiation and it is the 
most advanced stage of metaplasia and is a defining feature of malignant cells (Meng et 
al., 2012). Pathophysiology of cancer depends on factor controlling cell growth and 
differentiation. These factors include immunity, cell growth rate. Normal cellular growth is 
affected by protein encoded by the genetic materials in the nuclei. Therefore, alteration of 
gentic materials or mutation by environmental or endogenous factor could results in 
tumour development. The altered or mutant genes are generally called oncogenes which 
allow the uncontrollable celluar growth leading to tumour development (Bekher, 1992). 
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Mechanism of cancer development is a complex process and it is not well understood yet. 
Therefore, studies have linked mechanism to the risk factors and hypotheses have been 
developed accordingly.  
The important step of cancer development happens when the cellular DNA is altered or 
damaged by endogenous or exogenous source such as ionizing and non-ionizing radiation, 
hormones and viruses. Then, this will lead to an error in DNA synthesis or repair (Lee et 
al., 2013).  The damaged cells are required to be exposed to one or more promoting agent 
that facilitates development of uncontrolled cell growth. This stage is called promotion 
stage. Promoters may include environmental pollutants, drugs, and hormones. Failure to 
neutralise or regulate the cancer cells by apoptosis or cells death will lead to the 
progression of tumour development. 
Environmental factors and unhealthy lifestyle practices have been shown to be major risk 
factors in the carcinogenesis of different types of Cancers (Irigaray et al., 2007). These 
factors involves: smoking, alcohol consumption, unhealthy diet, medications, and 
ultraviolet exposures. 
Dietary factors and obesity have been linked to some types of cancers. Evidence shows 
that consumption of dietary fat may increase bile acids and cholesterol metabolites that 
may increase carcinogens in the body that are associated with colorectal cancers. Low 
dietry fibres also have been to be linked with increased risk of colonic cancer. Obesity is 
seen to be linked to an increased risk for breast, ovaries, and endometrium tumours in 
females (Forte et al, 2012; McTiernan, 2003). This effect is more linked to the high 
number of fat cells that produces oestrogen. Therefore, it has been suggested that high 
oestrogenic levels might increase cancer risk (McTiernan, 2003). 
Medications like Androgen -anabolic steroids have been linked to liver, prostate and breast 
cancers (Grossmann and Wittert, 2012: Friedenreich, 2000). External or environmental 
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factors such as air pollutants, radiation, and radon gas also have been linked to high 
incidence of cancers. Cancer also can be caused by viruses which are generally termed as 
oncogenic viruses. They can cause alterations in the cellular genomic material; thus 
leading to oncogenic process in susceptible individuals (Hausen, 1991) 
 
 1.14 Breast Cancer 
Breast cancer is the most common form of malignancy that has serious implications on the 
health of women worldwide, and ranks as the second leading cause of mortality in women. 
The main cause of breast cancer is still not completely understood (Ye et al., 2004). Breast 
cancer may develop by different factors such as genetic alteration, life-style, and obesity, 
higher level of specific hormones, tobacco and smoking. For instance, several studies have 
suggested that chronic inflammation is derived from smoking and tobacco, which increases 
the risk of breast cancer (Mink et al., 2002; Hecht, 2002). The pathology of breast cancer is 
classified into three categories according to its gene expression, receptors and 
immunohistochemistry characterisation (Table 1.2). This influences the prognosis of the 
disease and treatment response. The first type (Luminal subtype) is both estrogen receptor 
(ER) positive and progesterone receptor (PR) positive that constitutes for the majority of all 
breast cancer and is the least aggressive. Second type is human epidermal growth factor 
receptor-2 (HER2) positive that is approximately 25% and more aggressive than luminal. 
The final type is luminal triple-negative (basal-like) which is devoid of all receptors. This 
tumour or subtype is the most aggressive with worst prognosis (Gown, 2009; Schnitt, 2010). 
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Table 1.2: The main classification of breast cancer by gene expression profiling (Schnitt, 
2010). 
Molecular classification 
Luminal HER2 Basal 
Gene expression 
pattern 
High expression of ER 
and PR receptor and 
associated genes  
 
High expression of 
HER2 and other 
genes. 
 
High expression of basal 
epithelial genes, basal 
Cytokeratins. 
Clinical features The least aggressive.  
 
The majority of 
invasive breast cancers 
ER/PR positive. 
 
~25% more 
aggressive than 
luminal. 
Invasive breast 
cancers (~15%) 
ER/PR negative 
 
The most aggressive.  
 
Invasive breast cancers 
(~15%) 
Most ER/PR/HER2 
negative 
(„triple negative‟) 
 
Treatment 
response 
and outcome 
Respond to endocrine 
therapy (but response 
to tamoxifen and 
aromatase inhibitors  
 
Respond to 
trastuzumab 
(Herceptin) 
Respond to 
anthracyclinebased 
chemotherapy 
Generally. 
Worse 
prognosis. 
No response to endocrine 
therapy or trastuzumab 
(Herceptin) 
This type of tumour is not 
carry same poor prognosis 
 
1.15 Risk Factors for Breast Cancer 
Many risk factors increase the chances of developing breast cancer. Notably, age is 
considered the primary risk factor related to breast cancer. For instance, women aged under 
25 are less likely to develop breast cancer as there are 10 cases reported per 100,000 
women and at the age of 45. These cases rise by 100-fold (Dumitrescu and Cotarla, 2005). 
Interestingly, women who conceive a child before the age of 20 are less likely get breast 
29 
 
cancer as compared to women who have a child after the age of 30 (McPherson et al., 
2000). Furthermore, the greater risk of developing breast cancer, as the women gets older 
may be due to the changes in their hormonal activities (McPherson  et al., 2000). There are 
different risks factors that have been found to play an important role in producing breast 
cancer, such as diet and obesity. The human diet consists of a combination of both 
carcinogenic and anti-carcinogenic compounds contained within various foods. Specific 
types of these compounds may lead to the production of free oxygen radicals that cause 
DNA damage (Dumitrescu and Cotarla, 2005). The connection between obesity and breast 
cancer related to menopause where it is due to the high levels of endogenous oestrogen 
found in obese women who are postmenopausal. On the other hand, women who are 
premenopausal and obese are less likely to develop breast cancer (McTiernan, 2003). An 
alternative known risk factor of breast cancer is mammography density, where it is 
irrelevant whether the women are in the pre- or postmenopausal stage. The family history 
is another important risk factor, where a meta-analysis has previously demonstrated that 
there is a 12% chance of having another family member affected and 1% chance of having 
more than one family affected by breast cancer (Dumitrescu and Cotarla, 2005; Biglia et 
al., 2004 ). Moreover, up to 10% of breast cancer is referred as germline mutations. Two 
breast cancer mutations have been found the most common, BRCA2 gene followed by 
BRCA1 (McPherson et al., 2000: Roy et al., 2012). Exogenous hormones used after 
menopausal or the use of oral contraceptives increases the risk of breast cancer growth. 
Notably, there was a 24% greater risk of developing breast cancer when taking oral 
contraceptives and this risk reduces after 10 years of not taking them.    
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1.16 Diabetes as a Risk Factor for Cancer  
Both diabetes and cancer are widespread diseases that are considered to be a major cause 
of death every year worldwide. Cancer is the second most common cause of death, while 
diabetes is the seventh (Habib and Rojna, 2013). Moreover, the likelihood of increasing 
diagnosis of cancer patients being diabetic cannot be by chance, suggesting a link. Reports 
observed by clinicians dating back more than 50 years have considered an association 
between the two diseases. Joslin et al, 1959 stated, “Studies of the association of diabetes 
and cancer have been conducted over a period of years, but evidence of a positive 
association remains inconclusive” (Joslin et al., 1959). Many studies have suggested that 
the link between the two diseases is influenced by other factors such as type of diabetes. 
Several meta-analytical studies have suggested that some types of cancer are more likely to 
develop in diabetic patients than the general population (Giovannucci et al., 2010; Vigneri 
et al., 2009: Abe and Yamagishi, 2008). The Warburg effect is a theory that hypothesised 
high levels of glycolysis are found in many tumours. This is due to the tumours requiring 
high levels of energy in the form of ATP (Warburg, 1956).  Recently, most studies indicate 
the link between diabetes and cancer via different mechanisms, such as hyperglycaemia, 
hyperinsulinemia and inflammation (Coughlin et al., 2004; Griffiths et al., 2012). In 
addition, several epidemiological studies have suggested that the increased level of insulin-
like growth factor (IGF-1) is linked to many types of cancer such as liver, colon, kidney, 
pancreas and breast cancer (Coughlin et al., 2004; Statin, 2007). Furthermore, many 
studies have proposed that female patients with both Type 1 and Type 2 diabetes are at 
high risk of developing breast cancer, especially through metabolism due to 
hyperglycaemia (Vigneri et al., 2009; Xue and Michels, 2007; Michels et al., 2003). 
However, the exact mechanism is still not fully understood. Notably, many studies have 
shown that there are four mechanisms that may contribute to the association between Type 
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2 diabetes and breast cancer, as demonstrated in Figure 1.5 (Wolf and Rubinek, 2008). 
Notably, many studies have found that increased level of glucoses above 7 mmol/L after 
fasting glucose test had overexpression of insulin receptor in breast cancer (Belfiore and 
Malaguarnera, 2011; Papa and Belfiore, 1996; Rapp et al., 2006). Moreover, many studies 
have recently brought to light the benefits of metformin in diabetic patient in that it reduces 
both incidence and mortality of breast cancer (Ishibashi et al., 2013).  
                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 1.5: Mechanisms explain correlating type 2 diabetes and breast cancer. This 
Schematic explains the way insulin resistance develops (Wolf and Rubinek, 2008).  
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1.17 Vascular complaications in breast cancer: 
Breast cancer is known to have a high risk of developing vascular complications 
contributing to its development and its dissemination through metastasis. High incidence 
of venous thromboembolism (VTE) has been reported in many types of cancers including 
breast cancer particularly following chemotherapy and rises to approximately 18% in late 
stage of breast cancer (Kirwan et al, 2009; Caine et al, 2003). 
Several studies suggested that this hyper-coagulable state  reflected by VTE is associated 
with an increased level of plasma vascular endothelial growth factor (VEGF) a potent pro-
angiogenic growth factor, released by activated platelets (Byrne et al, 2007) . Angiogenesis 
is tightly regulated process through which new blood vessels are formed. This process is 
strongly stimulated by the tumour and well known as a tumour angiogenesis, a process 
mainly induced by VEGF produced by the cancerous cells undergoing hypoxia (Filho et al, 
2010). The abnormal new blood vessel formation will provide blood circulation to 
malignant cells assisting their growth and dissemination through metastasis. In addition, 
VEGF is also well known to increase vascular permeability, a critical event in 
angiogenesis also in inflammation which amplifies tumour angiogenesis. Different forms 
of VEGF have been detected at higher level of expression in the plasma or cancerous 
tissues and have been used as indicators of the stage of the progression of breast cancers 
(Heer et al 2001; Byrne et al, 2007; Kirwan et al, 2009). Other clinical studies have 
established the connections between the degree of VEGF expression with tumor 
aggressiveness reflected by microvessels density translated into patient's disease free and 
overall survival (Byrne et al, 2007). 
AGEs have been reported to cause increased endothelial dysfunction through interaction 
with RAGE (Smit and Lutgers, 2004; Tan et al., 2002) and are believed to be essentially 
responsible for the high-incidence of several vascular diseases leading to stroke and 
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peripheral vascular diseases for instance (Laakso, 1999; Rahman et al., 2007). AGEs affect 
all main functions of vascular cells in both extracellular endothelial cells and supportive 
mesanchymal cells and increased vascular permeability. In addition, it has been 
demonstrated that AGE- RAGE interactions result in the stimulation of angiogenesis 
through up-regulation of VEGF expression and VEGF receptor activation which contribute 
to the onset and development of vascular angiopatheis. Moreover, AGEs have been found 
to stimulate the growth and tube formation of human microvascular endothelial cells which 
are considered to be the key steps of angiogenesis.   
Similar changes of higher levels of VEGF expression is induced by AGEs affecting 
specifically pericytes leading to increasing vascular permeability and  angiogenesis 
resulting into earlier changes seen in diabetic retinopathy ,more supportive evidence 
obtained by blocking this through blocking  AGEs accumulation. Diabetic nephropathy 
have shown in vivo and vitro studies the pathological contribution of VEGF higher 
expression in mesangial cells and glomerular damage suggesting that AGEs may induce 
those changes and contribute to the development of increased permeability and clinical 
albuminuria which is an early evidence of diabetic nephropathy .other thrombogenic 
vascular changes is induced by reduction of nitric oxide NO which is known to possess an 
antithrombogenic pivotal role (Basta et al., 2004). 
 
1.18 AGEs and Cancer 
Numerous clinical and epidemiological studies have demonstrated that AGEs and their 
receptors are associated with various types of cancer through hyperglycaemia (Abe and 
Yamagishi, 2008; Jiao et al., 2011). During the tumour progression, the uptake of glucose 
is increased and may result in increased levels of AGEs (van Heijst et al., 2005). The 
modifications of AGEs have been found to contribute to malignancy, especially by their 
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influence on the DNA-glycation via oxidative stress and other various processes. Thus, the 
effect of AGEs on the DNA cause changes of gene expression and mutagenesis (Thornally 
et al, 2008). However, one recent study has shown that CML-AGEs increase the risk of 
colorectal cancers (Moy et al., 2013). Another possible explanation is that hyperglycaemia 
enhances the oxidative stress via AGEs, which regulate chronic inflammation and changes 
the immune function that is associated with cancer. In addition, the interaction between 
AGEs and RAGE will lead to the activation of a diversity of cell signalling pathways that 
are expressed in various tumours (Kuniyasu et al., 2002; Kim et al., 2008).  
  
1.19 Roles of AGE-RAGE in the Development of Cancer 
RAGE is a multiligand receptor that have been expressed and up regulated in many types 
of cancer (Rojas et al., 2011: Abe and Yamagishi, 2008). Many studies on animals and 
clinical data reinforce the belief that there is a direct link between RAGE activation that 
leads to progression of invasive and metastasis tumour cells (Riehl, et al., 2009; Sparvero 
et al, 2009). Recent studies have suggested that there is an increased expression of RAGE 
during inflammation and tumour growth. For instance, this is demonstrated in colorectal, 
breast, lung, gastric, melanoma and prostatic cancer (Abe and Yamagishi, 2008; Abe et al., 
2004). This phenomena is considered to occur due to RAGE‟s ability to readily bind to 
many types of ligands, which then trigger the activation of signalling pathway and 
stimulate tumour growth. Then these cells proliferate, invade and metastasize that plays an 
important role in poor prognosis (Jing et al., 2008). Among those receptor ligands that 
interact with AGEs and link to tumour growth, are high-mobility group box-1 (HMGB1, 
mphoterin) and S100. Furthermore, RAGE engagement with AGEs activates multiple 
signalling pathways such as reactive oxygen species, p38, ERK1, ERK2, JAK/STAT and 
SAPK/JNK (Rojas et al, 2011). The interaction between the AGEs and RAGE can 
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generate oxidative stress in the cells that contribute to cancer growth (Jiao et al., 2011). 
The interaction between AGEs and RAGE, when induce the inflammation, results in the 
expression of NFκB that plays an important role in cellular processes and cell cycle as 
demonstrated in Figure 1.6 (Rojas  et al., 2011; Sinha et al., 2008; Kim et al., 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6:  Schematic diagram of the interaction between RAGE ligands (AGE) and 
RAGE leading to numerous signalling pathways. These pathways are associated to 
tumours (Rojas et al., 2011). 
 
 1.20 AGEs and Breast Cancer 
In 2009, there were approximately 49,000 cases within the UK of women 
diagnosed with diabetes and breast cancer simultaneously (Cancer research, UK). Some 
studies have reported a correlation between diabetes and cancer (including breast cancer). 
However, underlying molecular link between diabetes and cancer remains to be elucidated. 
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There is a growing body of evidence to show that AGEs-RAGE interactions stimulated the 
growth of human cancer cells, but little is known regarding the molecular mechanism 
involved. Much attention has been given to the most aggressive phenotype of breast cancer 
with the identification of the roles that increasing RAGE expression, but AGE role in 
breast cancer is still unclear (Radia et al., 2013; Korwar et al., 2012). However, biological 
effects of AGE and AGE-RAGE in breast cancer cells are poorly investigated.  
  
Aims and Objectives 
The aim of this current study was to understand the role of AGEs in breast cancer. The 
main objectives are: 
1. To prepare endotoxin and sugar free BSA-AGEs using glucose and methylglyoxal. 
2. To assess the effects of BSA-AGE concentrations on the proliferation, migration and 
invasion of MDA-MB231 (non-hormone dependent) and MCF-7 (hormone dependent) 
breast cancer cell lines in vitro. 
3. To determine the molecular signalling pathway mechanism that underlies the effect 
of BSA-AGEs on the MDA-MB231 and MCF-7 breast cancer cell lines in vitro.  
4. To investigate the expression of RAGE-AGE involved on the MDA-MB231 and 
MCF-7 breast cancer cell lines in vitro. 
0 
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34 
 
Chapter 2. Materials and Methods 
2.1 Materials 
 Breast cancer cell lines MDA-MB-231 and MCF-7 (American Type Culture Collection, 
Manassas, VA, USA) 
 Conical centrifuge tubes, sterile (Scientific Laboratory Supplies, Nottingham, UK) 
 Coverslips, Thermanox® plastic, sterile (Nunc™, Fischer Scientific, Loughborough, 
UK) 
 Cryo-tubes, sterile (Nunc corporation, Roskilde, Denmark) 
 Dialysis tubes (Camlab Limited, Cambridge, UK) 
 Eppendorf tubes, sterile (Scientific Laboratory Supplies, Nottingham, UK) 
 Gloves, sterile (Scientific Laboratory Supplies) 
 Hypodermic needles, sterile Plastipak (Scientific Laboratory Supplies) 
 Nitrocellulose membrane (Schleicher and Schuell, London, UK) 
 Parafilm (Scientific Laboratory Supplies) 
 Pierce™ high capacity endotoxin removal resin (Thermo Scientific™, Rockford, USA) 
 Razor blades (Kratos Analytical Limited, Manchester, UK) 
 Syringe, sterile Plastipak (Scientific Laboratory Supplies) 
 Syringe filter, Acrodisc® 32 mm, 0.2 m of porosity (Pall Corporation, Portsmouth, 
UK) 
 Tissue culture flasks T25, T75 (Nunc™) 
 Tissue culture plates in 6-well, 24-well, 96-well formats (Nunc™) 
 Transwell® 24-insert plate (Nunc™) 
 Universal tubes, sterile, 6 mL, 30 mL (Scientific Laboratory Supplies) 
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2.2 Chemicals and Reagents  
 Acetic acid (Fisher Scientific UK Ltd, Loughborough, UK)  
 Acrylamide/Bis solution 40% (Bio-Rad Laboratories, Hertfordshire, UK) 
 Ammonium persulphate (Sigma-Aldrich, Dorset, UK) 
 Antibiotics penicillin, streptomycin with L-glutamine in 0.9% NaCl (Sigma-Aldrich) 
 Ascorbic acid (Sigma-Aldrich) 
 Benzamidine (Sigma-Aldrich) 
 Beta-glycerophosphate (Sigma-Aldrich) 
 Bovine serum albumin, fraction V (Sigma-Aldrich) 
 Bovine gelatine (Sigma-Aldrich) 
 Brij® 35 (Sigma-Aldrich) 
 Bromophenol blue stain (Sigma-Aldrich) 
 Calcium chloride (Sigma-Aldrich) 
 ColorBurst electrophoresis marker for SDS-PAGE (Sigma-Aldrich) 
 Coomassie brilliant blue R-250 (Sigma) 
 D-glucose (BDH Ltd, Dorset, UK) 
 Dimethyl sulfoxide (Sigma-Aldrich) 
 Dithiothreitol (Sigma-Aldrich) 
 Dulbecco‟s modified Eagle‟s medium (Lonza Biowhittaker, Fisher Scientific) 
 ECL chemiluminescent detection kit (Amersham Biosciences, Buckinghamshire, UK) 
 Ethanol (Fisher Scientific UK Ltd) 
 Ethylene diamine tetra acetic acid (Sigma-Aldrich) 
 E-toxate kit (Sigma-Aldrich) 
 Fibroblast growth factor basic (FGFb, R&D systems, Abingdon, UK) 
 Foetal bovine serum (FBS, Lonza Biowhittaker, Fisher Scientific) 
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 Glyceraldehyde 3-phosphate dehydrogenase, mouse monoclonal antibody (Abcam, 
Cambridge, UK) 
 Giemsa stain (Sigma-Aldrich) 
 Glycerol (Sigma-Aldrich) 
 Glycine (BDH Ltd) 
 Growth factor-reduced Matrigel™ (Becton Dickinson, Oxford, UK) 
 Horseradish peroxidase-conjugated secondary antibodies (Dako UK Ltd, 
Cambridgeshire, UK) 
 Hydrochloric acid (Sigma-Aldrich) 
 Isopropanol (Sigma-Aldrich) 
 Isoton® II diluent (Fisher Scientific UK Ltd) 
 Isotype control from murine myeloma, immunoglobulin IgG1 (Sigma-Aldrich) 
 Lysozyme (Sigma-Aldrich) 
 Leupeptin (Sigma-Aldrich) 
 2-Mercaptoethanol (Sigma-Aldrich) 
 Methanol (Sigma-Aldrich) 
 Methylene blue stain (Sigma-Aldrich) 
 Methylglyoxal (Sigma-Aldrich) 
 N, N, N′, N′-tetramethylethylenediamine (Sigma-Aldrich) 
 Paraformaldehyde (Sigma-Aldrich) 
 Pepstatin A (Sigma-Aldrich) 
 Phenylmethylsulfonyl fluoride (Sigma-Aldrich) 
 Phosphate-buffered saline (Sigma-Aldrich) 
 Phospho-extracellular signal-regulated kinase, mouse monoclonal antibody (Santa Cruz 
Biotechnology) 
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 Protease inhibitor cocktail (Sigma-Aldrich) 
 Protein estimation kit (Bio-Rad Laboratories, Hertfordshire, UK) 
 Rabbit monoclonal anti-mouse antibody-fluorescein isothiocyanate (Invitrogen, Paisley, 
UK) 
 Receptor for advanced glycation endproducts (RAGE, E-1), monoclonal antibody 
(Santa Cruz Biotechnology, Heidelberg, Germany) 
 Skimmed milk powder (Local store, Manchester, UK) 
 Sodium azide (Sigma-Aldrich) 
 Sodium bicarbonate (Sigma-Aldrich) 
 Sodium chloride (BDH Ltd) 
 Sodium deoxycholate (Sigma-Aldrich) 
 Sodium dihydrogen phosphate (Sigma-Aldrich) 
 Sodium dodecyl sulphate (BDH Ltd) 
 Sodium fluoride (Sigma-Aldrich) 
 Sodium hydroxide (BDH Ltd) 
 Sodium orthovanadate (Sigma-Aldrich) 
 Sodium phosphate dibasic (Sigma-Aldrich) 
 Sodium pyrophosphate (Sigma-Aldrich) 
 Total-extracellular signal-regulated kinase, rabbit polyclonal antibody (Santa Cruz 
Biotechnology) 
 Tris(hydroxymethyl)methylamine (BDH Ltd) 
 Triton X-100 (Sigma-Aldrich) 
 Trypan blue (Sigma-Aldrich) 
 Trypsin/EDTA (Sigma-Aldrich) 
 Tween 20 (Sigma-Aldrich) 
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2.3 Solutions and Buffers 
 Activation buffer: 50 mM Tris-HCl, 0.2 M NaCl, 5 mM CaCl2 and 0.02% Brij 35. 
 Ammonium persulfate solution (10%): 0.1 g of ammonium persulfate dissolved in 1 
mL of distilled water (dH2O). The buffer was stored at 4°C. 
 Blocking buffer (1% BSA in TBS-Tween): 1 g of bovine serum albumin (BSA) 
added to 100 mL of tris-buffered saline (TBS)-Tween, pH adjusted to 7.4. The buffer was 
stored at 4°C for one week. 
 Blocking buffer (5% milk in TBS-Tween): 5 g of skimmed milk added to 100 mL of 
TBS-Tween, pH adjusted to 7.4. The buffer was stored at 4°C for one week. 
 BSA solution (0.1%): 10 mg of BSA dissolved in 10 mL of dH2O. The solution was 
stored at 4°C for one week. 
 Cell lysis buffer for the extraction of  RAGE: 10 mM Tris HCl (pH 7.4), 50 mM NaCl, 5 
mM EDTA, 1% Triton X-100, 0.05% SDS, 50 mM sodium fluoride, 100 uM sodium 
orthovanadate, 10 mM beta-glycerophosphate, 10 mM sodium pyrophosphate, 100 
ug/ml PMSF, 3 mM benzamidine, 1 mM dithiothreitol, 10 uM leupeptin, 5 uM pepstatin 
A and cocktail of protease inhibitors from Sigma. 
 Destaining solution: 250 mL of methanol added to 70 mL of acetic acid to make a 
volume of 1 L with (dH2O). 
 Electrophoresis buffer: 12.02 g of Tris-base, 4 g of SDS and 57.68 g of glycine 
dissolved in 2 L of dH2O. The buffer was kept at room temperature. 
 Laemmli sample buffer: For 10 mL, mix 4 mL of 10% SDS, 1.2 mL of 1 M Tris-Cl (pH 
6.8), 200 μL of 1% bromophenol blue, and 2.6 mL of H2O. Add 2 mL of fresh DTT (1 
M) from stock. (For experiments with radioactive methionine, use only 500 μL of fresh 
DTT [1 M], and boost the volume of H2O to 4.1 mL. 
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 Radioimmunoprecipitation assay (RIPA) buffer: 25 mM Tris-HCl (pH 7.5), 150 mM 
NaCl, 0.5% sodium deoxycholate, 0.5% SDS, 1 mM EDTA, 1 mM sodium 
orthovanadate, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% Triton-X100 and 1 M 
Leupeptin. 
 Renaturation buffer:  of 2.5% Triton X-100 (v/v). 
 Sample buffer (non-reducing): 0.5 M Tris-HCL, pH 6.8 ( 2.5 mL ), glycerol 2.0mL 
10% (w/v) SDS (4.0 mL), 0.1% bromophenol blue (0.5mL) with (dH2O) to 10.0 mL.                 
 Sample buffer: 1.51 g of Tris-base, 4 g of SDS and 0.004 g of bromophenol blue 
added to 20 mL of glycerol and 10 mL of 2-mercaptoethanol to make a volume of 100 
mL of dH2O. The pH was adjusted to 6.8 and the buffer was stored at -20°C. 
 Separating buffer: 45.5 g of Tris-base and 1 g of SDS dissolved in 250 mL of dH2O, 
pH adjusted to 8.8. The buffer was kept at room temperature.  
 Separating gel (12.5% acrylamide): 2.5 mL of separating buffer, 4.2 mL of dH2O 
were mixed with 3.3 mL of acrylamide/Bis solution 40%. The addition of 100 L of 10% 
ammonium persulphate and 10 L of TEMED allows the solution to polymerize within 
20-25 minutes.  
 Sodium phosphate buffer (0.1 M): 3.1 g NaH2PO4 and 10.9 g Na2HPO4 dissolved in 
1 L of dH2O, pH adjusted to 7.4. The sodium azide (3 mM) was added to prevent any 
contamination. The buffer was stored at 4°C for up to one month. 
 Stacking buffer: 15 g of Tris-base and 1 g of SDS dissolved in 250 mL of dH2O, pH 
adjusted to 6.8. The buffer was kept at room temperature.  
 Stacking gel (5.5% acrylamide): 2.5 mL of stacking buffer, 6.1 mL of dH2O were 
mixed with 1.45 mL of acrylamide/Bis solution 40%. The addition of 100 L of 10% 
ammonium persulphate and 10 L of TEMED allows the solution to polymerize within 
10-15 minutes. 
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 Staining solution: 2.5 g of Coomassie blue added to 500 mL of methanol and 100 
mL of acetic acid to make a volume of 1 L of dH2O. The solution was filtered and kept at 
room temperature. 
 TBS-Tween: 2.422 g of tris-base and 16.36 g NaCl were dissolved in 2 L of dH2O 
and 2 mL of Tween 20. The pH was adjusted to 7.4 and the solution was kept at room 
temperature. 
 Towbin buffer: 1.5 g Tris-base, 7.2 g glycine and 0.167 g SDS dissolved in 400 mL 
of dH2O, pH adjusted to 8.3. The buffer was kept at room temperature. 
 Transmembrane protein extraction buffer: 10 mM Tris-HCl (pH 7.4), 50 mM 
sodium fluoride, 100 M sodium orthovanadate, 10 mM -glycerophosphate, 10 mM 
sodium pyrophosphate, 100 g/mL phenylmethylsulfonyl fluoride, 10 mM dithiothreitol, 
3 mM benzamidine, 1 mM dithiothreitol, 10 M leupeptin, 5 M pepstatin A and a 
cocktail of protease inhibitors. 
 
2.4 Equipment and Software 
 Analytical balance (Sartorius Machatronics Ltd, Epson, UK) 
 Automated cell counter TC10 (Bio-Rad Laboratories) 
 Class II microbiological safety cabinet (Walker Safety Ltd, Derbyshire, UK) 
 CO2 incubator (Lab Impex Research Ltd, Abbey, UK) 
 Coulter Counter (Beckman Coulter, Buckinghamshire, UK) 
 Centrifuge 5415D (Eppendorf, Hamburg, Germany) 
 FACS Calibur Flow Cytometer and FACScan analysis software (Becton Dickinson) 
 Fujifilm FinePix S2 Pro 6.17 MP digital SLR camera (Fujifilm UK Ltd, Bedford, 
UK) 
 G Box Chem HR 16 with GeneSnap software (Syngene, Cambridge, UK) 
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 Ice maker (Borolab Ltd, Abingdon, UK) 
 Image J analysis software (http://rsbweb.nih.gov/ij/index.html) 
 Inverted phase contrast microscope (TMS, Nikon, Tokyo, Japan)  
 Laboratory freezer Bio cold (Scientific Laboratory Supplies) 
 Laboratory fridge Bio cold (Scientific Laboratory Supplies) 
 Laboratory pH/mV/temperature meter AGB-75 (Medical Scientific Instruments, 
Hertfordshire, England) 
 LTE IP 30 incubator (Scientific Laboratory Supplies) 
 Luminescence spectrometer model LS 30 (Perkin Elmer LAS Ltd, 
Buckinghamshire, UK) 
 Microsoft office 2007 (Microsoft, USA) 
 Sigma laboratory centrifuge 3K10 (Sigma Laboratories, Germany) 
 Stuart Magnetic stirrer hotplate (Fisher Scientific UK Ltd) 
 Trans-blot SD semi-dry transfer cell (Bio-Rad Laboratories) 
 Ultrospec 2000 UV-VIS spectrophotometer (Amersham Pharmacia Biotech Ltd, 
Hertfordshire, UK) 
 Water bath (Scientific Laboratory Supplies) 
 Water purification system (Millipore UK Ltd, Watford, UK) 
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2.5 Methods  
2.5.1 In vitro Glycation Reactions 
The preparation of bovine serum albumin (BSA) derived advanced glycation endproducts 
(BSA-AGEs) was based on an established procedure previously described by Mashilipa et 
al. (2011). Briefly, BSA or lysozyme (10mg/ml) was incubated with glucose (0.5M) or 
methylglyoxal (0.1 M) in 0.1M sodium phosphate buffer containing 3mM sodium azide, 
pH 7.4 at 37 °C for different incubation times or different concentrations with 
methylglyoxal (0.01 M, 0.5 M, 0.1 M). The sodium azide was added to prevent the growth 
of bacteria and fungi during the glycation reaction, which lasted for 3 days in the presence 
of methylglyoxal and 15 days in the presence of glucose at 37°C. Non-modified BSA and 
lysozyme underwent the same conditions of preparations but in the absence of glucose or 
methylglyoxal. All glycation reactions were carried out in triplicate. 
 
2.5.2 Dialysis of BSA-AGEs  
This method was used for the removal of free sugars from the glycated proteins via dialysis 
against distilled water (Figure 2.1). Special dialysis tubes were utilised and sterilized after 
being boiled for at least 30 minutes in a solution composed of 10 mM sodium bicarbonate 
/1mM EDTA. One end of the tube was tied then the protein samples were poured into the 
tube after which the other end of the tube was sealed. The dialysis tubing was transferred 
into a beaker containing 2 L of distilled water and 200 µL of chloroform were added to 
prevent any bacterial and fungi contamination. Dialysis was conducted by stirring the 
samples at 4 ºC. The water was exchanged over three days until equilibrium was reached. 
Finally, the samples were transferred into clean tubes and stored at -20°C until further use. 
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Figure 2.1:  Illustration of the dialysis set-up 
 
2.5.3 Endotoxin Removal from BSA-AGEs 
The BSA-AGEs were prepared in non-sterile conditions with a high risk of bacterial 
endotoxin contamination. The bacterial endotoxins are small pro-inflammatory particles, 
which can alter the proper biological effects of BSA-AGEs on cells. Because of their small 
size, filtration of the BSA-AGE solution using a standard filter with 0.22 m of porosity 
would be insufficient to get rid of the bacterial endotoxins from the solution. Therefore, in 
sterile conditions using the safety cabinet, the endotoxin removal was performed by 
subjecting the sample solution to Pierce™ high capacity endotoxin removing gel resin 
columns. These resin columns has a special filter containing molecules with affinity for 
endotoxin were regenerated by cycles of washes corresponding to 5 resin-bed volumes of 
1% sodium deoxycholate. BSA-AGE and non-modified BSA solutions mixed with a basal 
medium with phenol red (tracking dye) were fulfilled the gel resin column with a total 
volume of 1 mL. After 2 hours at room temperature, the sample was collected in a sterile 
pyrogen-free tube and kept in the freezer -20 ºC. 
Dialysis 
membrane 
AGE 
compound 
Sterile water 
Stirrer bar 
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2.5.4 Endotoxin Detection in BSA-AGEs 
The remaining of bacterial endotoxins in the sample was detected by using E-toxate kit 
based on Limulus Amebocyte lysate assay. Briefly, 100 L of samples, water and 
endotoxin standards were added to the sterile glass pyrogen-free tubes. E-toxate working 
solution (100 L) was added to each test tube containing the sample. The tubes were then 
mixed gently and covered with Parafilm® for 1 hour at 37ºC. Subsequently, the tubes were 
gently inverted to 180º for the observation of a potential formation of a hard gel, which 
was considered as a positive test with high endotoxin concentration. The negative tests 
corresponded to the observation of soft gels, turbidity, viscosity or clear liquid. The 
endotoxin concentration was calculated using the following formula: 
 
 
 
2.5.5 Standard Curve for Protein Determination 
BSA was used as a standard protein. Serial dilutions of BSA (1 g/L) were made with 
dH2O up to 100 L, establishing a range of protein varying from 0 g to 40 g/L (See 
Table 2.1). Protein sample solution (10 L) was mixed with dH2O (90 L). Bio-Rad 
protein assay reagent (2 mL) was added to each tube containing 100 L of BSA or diluted 
BSA or protein sample. Absorbance of the protein solution was measured at 570 nm using 
a spectrophotometer. A standard curve required for the determination of sample protein 
concentration was established from the serial dilution of BSA as shown in (Figure 2.2). 
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Table 2.1 Prepatation of a Serial Dilutions of BSA for standard curve. 
Stock 0.1% BSA 
(µL)  
Distilled water 
(µL)  
Bio-Rad reagent 
(mL)  
0 100 2 
10 90 2 
20 80 2 
40 60 2 
 
 
 
Figure 2.2:  Standard curve for protein estimation. 
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2.5.6 Detection of Crosslinked BSA-AGEs using SDS-PAGE 
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out 
to assess the integrity and cross-linking of glycated proteins. This method separates the 
denatured and negatively charged glycated proteins according to their molecular weight 
(Laemmli, 1970). The protein samples were denatured in 0.5 M Tris-HCl buffer (pH 6.8) 
containing 1% SDS (w/v), 1% 2-mercaptoethanol (v/v) and 20% glycine (v/v) and boiled 
for 5 minutes. The protein samples were loaded into the wells and migrated alongside a 
standard molecular weight marker. Bromophenol blue (3 µL) was added for protein 
tracking, and the electrophoresis was performed using the mini-Protean®3 apparatus. At 
the end of the complete protein separation, the gels were stained in a staining solution 
containing Coomassie brilliant blue R-250, methanol and acetic acid for 30 min at room 
temperature. The bands corresponding to the proteins were revealed after destaining the 
gels in the solution composed of methanol and acetic acid only for 15 min at ambient 
temperature. 
 
2.5.7 Analysis of Crosslinked BSA-AGEs using G Box 
After glycated protein separation by SDS-PAGE, followed by staining with Coomassie 
blue then destaining with methanol, the level of cross-linkage was assessed using an image 
analysis system. . Bands containing a mix of proteins two or more polypeptides may result 
from the occurrence of polypeptides that normally form noncovalent associations with 
each other or with other polypeptide types. This system used to estimate the relative 
quantities of monomeric, dimeric, trimeric and tetrameric species that resolved by SDS-
PAGE. Briefly, the destained gels revealing the stained bands on a clear background were 
analysed using GeneSnap software with Gene tool image analyser, which allow 
transferring data directly into excel sheet. 
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2.5.8 Measurements of fluorescent BSA-AGEs 
The formation of fluorescent BSA-AGEs was confirmed by the assessment of their 
characteristic fluorescence emission spectra at 420 nm in response to an excitation at 350 
nm, measured with a fluorescence spectrophotometer. BSA-AGEs and non-modified BSA 
solution (0.2 mL) were diluted with dH2O to a final concentration of 1 mg/mL. The 
reliability and accuracy of the instrument was checked by the use of fluorescent intensity 
standards to monitor its performance and by the use of quinine sulphate (1 ng/mL) in 
H2SO4 for its calibration. Fluorescence of BSA-AGEs was expressed in arbitrary units 
(AU) per mg of proteins.  
 
2.6 Culture of Breast Cancer Cell Lines MDA-MB-231 and MCF-7 Cells 
Cell culture is considered one of the most crucial techniques that have been discovered in 
the few decades. Notably, cell culture has the ability to control the physicochemical 
environment (such as the pH, temperature, carbon dioxide) to maintain constant 
environment during the experimentations All the procedure and experiment in this thesis 
were carried out in a sterile environment in culture room and safety cabinet. Ethanol (70% 
volume/ volume) was used for cleaning all surfaces. 
 
2.6.1 Heat-Inactivation of the Foetal Bovine Serum (FBS) 
The foetal bovine serum (FBS) was inactivated for 30 minutes in a water bath adjusted to 
56°C. For a complete inactivation of the serum compliment, the bottle was regularly 
shaken. The serum was previously stored in the freezer; the frozen FBS was subsequently 
thawed at 37°C in a water bath before the heat-inactivation. The heat-inactivation of the 
serum avoided any cell activation or inflammation in response to serum proteins. To avoid 
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repeated freeze/thaw cycles, the heat-inactivated serum was aliquoted into sterile 30 mL 
universal tubes and stored at -20°C.  
 
2.6.2 Preparation of Breast Cancer Cell Line Culture Medium 
The complete medium prepared for the culture of both breast cancer cell lines MCF-7 and 
MDA-MB-231 was composed of Dulbecco's modified Eagle‟s medium (DMEM) 
containing 4.5 g/L glucose and supplemented with 10% heat-inactivated (FBS) and 100 
U/mL penicillin, 100 g/mL streptomycin), and 2 mM glutamine.  
 
2.6.3 Culture of Breast Cancer Cells 
MDA-MB-231 and MCF-7 breast cancer cell lines were obtained from American Type 
Culture Collection (Manassas, VA, USA) and cultured in T-25 flasks in complete medium 
at 37°C in 5 % CO2 -incubator.  
 
2.6.4 Trypsinization of Breast Cancer Cells 
After MCF-7 and MDA-MB231 cells reached 80-90% confluence, the culture medium was 
removed and the cells were rinsed twice with 5 mL of sterile PBS. The cells were 
subsequently exposed to 1 mL of 0.05% trypsin 0.02% EDTA which allowed cell 
detachment by enzymatic digestion at 37°C. After 2-3 minutes of incubation, the floating 
cells were collected in a sterile 30 mL universal tube and the trypsin was neutralized by the 
addition of the complete medium. After 5 minutes of centrifugation at 300 g at room 
temperature, the supernatant was discarded and the cell pellet was re-suspended in a fresh 
complete medium for subculture or in serum-poor medium (SPM; basal medium 
supplemented with 2.5% FBS) according to the assay used throughout the study. 
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2.6.5 Freezing of Breast Cancer Cells 
The MCF-7 and MDA-MB-231 confluent cells corresponding to 1 x 10
6
 cells were 
detached from one T-25 flask according to the trypsinization method previously described. 
After the standard conditions of centrifugation, the supernatant was discarded and the cell 
pellet was re-suspended in 250 L of complete medium and 750 L of freezing medium 
composed of 10 % DMSO and 90 % FBS. The freezing medium containing the cells was 
equally distributed in 3 cryovials containing approximately 3 x10
5
 cells. The cells were 
gradually frozen starting in the freezer at – 20 ºC for 30 minutes then placed in the freezer 
at -80 ºC overnight before being stored in liquid nitrogen (– 192 ºC). 
 
2.6.6 Thawing of Breast Cancer Cells 
The cryotube containing the frozen cells was taken from the liquid nitrogen (for long 
storage) or from the freezer -80 ºC (for short storage). The cryovial was gently defrosted at 
37 °C in the water bath until the freezing medium was completely melted but remained 
cold because of the presence of DMSO, a cryo-protector reagent that becomes toxic to the 
cells at high temperatures. The cryovial was sprayed with 70 % ethanol inside the safety 
cabinet then the cells were transferred in a universal tube containing complete medium for 
centrifugation. The cell pellet was re-suspended in 3 mL of complete medium and the cells 
were seeded in a T-25 flask for incubation.  
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2.6.7 Cell Counting 
The cells were counted using a Beckman-Coulter counter based on 50 L of cell 
suspension diluted in 10 mL of isotonic solution and only 0.5 mL of diluted cell suspension 
were counted. The reading was taken three times and the cell concentration was calculated 
according to the following formulas: 
Mean of cell number = Mean of cell counts X (10/0.05) = Mean X 200 (dilution factor) = 
N 
Cell concentration (Mean of cell number/mL) = N / 0.5 mL (volume counted by the cell 
counter) 
  =Mean X 200 / 0.5 = Mean X 400 (dilution factor) 
 
2.7 Effect of BSA-AGEs on Breast Cancer Cells 
2.7.1 Cell Proliferation Assay  
The MDA-MB-231 cells (2.5 x 10
4 
/ mL) and MCF-7 cells (5 x 10
4
 / mL) in 0.5 mL of 
complete medium (10 % FBS) were seeded in 24-well plates. After 4 hours of incubation 
allowing the cells to attach to the bottom of the well, the medium was changed to a serum-
poor medium (SPM) supplemented with 2.5% FBS in the presence or absence of different 
concentrations (25 – 200 g/mL) of BSA-AGEs and non-modified BSA. Each condition 
was performed in triplicate. After 72 hours of incubation, the cells were detached in 250 
L of 0.05% trypsin / 0.02% EDTA then each cell suspension was diluted in 10 mL of 
isotonic solution and counted using a Beckman-Coulter counter.  
 
2.7.2 Cell Viability Assay  
The cell viability was assessed using a haemocytometer, a counting chamber analysed by 
TC10™ automated cell counter. MDA-MB-231 cells (2.5 x 104 / mL) and MCF-7 cells (5 
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x 10
4
 / mL) in 0.5 mL of complete medium were seeded in each well of 24-well plate. 
After 4 hours of incubation, the culture medium was replaced with SPM in the presence or 
absence of different concentrations (25 – 200 g/mL) of BSA-AGEs and non-modified 
BSA. Each condition was performed in triplicate. After 72 hours of incubation, the cells 
were washed with 0.5 mL of sterile PBS then detached by enzymatic digestion with 250 
L of 0.05% trypsin / 0.02% EDTA for 2-3 minutes. Then 20 µL of the cell suspension 
were mixed with 20 µL of 0.4% trypan blue, then, 10 L of this mixture was loaded into 
each side of the haemocytometer. The cells were visualised by light microscopy. After 
staining, the viable cells appeared colourless and bright as they exclude the dye, while the 
dead cells appeared blue. The number of cells was counted and the percentage of viable 
cells was calculated using the equation below:  
 
                   
                                               
                     
   
 
2.7.3 Cell Migration Assay using the Scratch Wound-Healing Method 
The MDA-MB-231 cells (5 x 10
4 
/ mL) in 1 mL of complete medium were seeded on 
Thermanox
®
 plastic coverslips (on the side treated for cells) in each well of a 24-well plate. 
After 24 hours of incubation, the cells reached the pre-confluence on the coverslips; the 
culture medium was changed to SPM for a further 24 hours of incubation. At confluence, 
the coverslip fully covered with the cells was removed from the well with a sterile forceps 
and the cells were bathed 3 times in a sterile universal tube containing sterile PBS. Each 
monolayer was subsequently wounded with a sterile razor blade on two sides of the 
coverslip, which gave the formation of two wound edges per coverslip with cell-denuded 
areas. Dislodged cells and cell debris were removed with sterile PBS. The coverslips with 
wounded cell monolayers were returned to the well containing SPM with or without 
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different concentrations (25 – 200 g/mL) of BSA-AGEs and non-modified BSA for 24 
hours of incubation. Each condition was performed in duplicate. At the end of the 
experiment, the cells were then fixed, rinsed with PBS then 100% ethanol was added for 5 
minutes and the cells were left to dry at room temperature. The cells were stained with 
0.1% methylene blue for 2 minutes and washed abundantly with distilled water to reveal 
the wound recovery. Four pictures from the wound edge of each side were taken to assess 
the cell migration by counting the number of the migrated cells and by measuring the 
distance of the cell migration using Image J software (http://rsbweb.nih.gov/ij/indix.html).  
 
2.7.4 Cell Migration Assay using Boyden Chamber Method 
In contrast to MDA-MB231 cells, which fully covered the coverslips, the MCF-7 cells 
grew mainly in clusters with the apparition of cell-denuded areas. Therefore, to assess the 
effects of BSA-AGEs on MCF-7 cell migration, the Boyden chamber method was used. 
The Boyden chamber, also called Transwell®, is composed of two chambers: the upper 
chamber is an insert, which has at the bottom a porous membrane with 8 m of porosity 
and the lower chamber corresponds to the well of the plate. To avoid the increase of 
inactivated cell migration through the porous membrane because of the gravity, the porous 
membrane was covered with a thin layer of 0.1 % gelatine (20 L) and left to dry in the 
safety cabinet (Figure 2.3). 
 
MCF-7 cells (1 x 10
5 
/mL) in 100 L of complete medium were seeded on the porous 
membrane of the upper chamber and bathed in 400 l of SPM in the presence or absence 
of different concentrations (25 – 200 g/mL) of BSA-AGEs and non-modified BSA for 24 
hours of incubation. Each condition was performed in duplicate. After 24 hours of 
incubation, the non-migrated cells on the upper side of the porous membrane were 
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removed using cotton swab soaked with PBS. The cells, which migrated across the porous 
membrane, were fixed with 4% paraformaldehyde (PFA) then stained with 0.1% Giemsa 
stain for cell counting of the membrane using a Zeiss optical microscope.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3:  Schematic representation of Boyden Chamber. 
 
2.7.5 Cell Invasion Matrigel™ Assay 
The Matrigel
TM
, a growth factor-reduced reconstituted basement membrane, was diluted 
(1:6) in serum-free medium then (20 L) poured onto the porous membrane of a 
Transwell® 24-insert plate. The plate was incubated for 30 minutes to allow the gel to 
polymerise. MDA-MB-231 cells were seeded at 1 x 10
4 
/ 100 L in SPM (in the upper 
chamber of the Transwell®) in the presence or absence of different concentrations (25 – 
200 g/mL) of BSA-AGEs and non-modified BSA (in the well corresponding to the lower 
chamber of the Transwell®). Each condition was performed in duplicate. After 24 hours of 
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Plate well 
Invasive cells 
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incubation, the non-migrated cells located on the upper side of the porous membrane were 
removed using cotton swab soaked with PBS. The cells, which migrated across the porous 
membrane, were fixed with 4% PFA then stained with 0.1% Giemsa stain for cell counting 
using a Zeiss optical microscope. 
 
2.7.6 Gelatine Zymography 
The matrix metalloproteinase (MMP) activities in the cell-culture media, which had been 
used for cell invasion assay, were assessed. The medium was collected and centrifuged at 
400 g for 15 minutes at 4°C. Protein concentration was determined using the Bio-Rad 
protein assay (see section 2.5.5), and the samples (100 g of proteins) were mixed with an 
equal volume of non-reducing sample buffer. The samples were incubated for 10 minutes 
at room temperature and subjected to electrophoresis on 7.5% SDS-PAGE gels containing 
1 mg/mL gelatine, used as a substrate. The gels were washed in renaturation buffer for 30 
minutes at room temperature to remove SDS and to renature the MMPs in the gels. Then 
the gels were rinsed in activation buffer for 30 minutes to activate the MMPs. The gels 
were incubated overnight at 37°C with fresh activation buffer then stained with 0.5% 
Coomassie blue R-250 for 2 hours at room temperature. After destaining, MMP gelatinase 
activity was detected as a white band on a dark background and quantified by densitometry 
using Image J software. 
 
2.7.7 Preparation of Cell Lysates and Western Blot Analysis 
The MDA-MB-231 cells (3 x 10
5 
/mL) and MCF-7 cells (6 x 10
5 
/mL) in 2 mL of complete 
medium were seeded in 6-well plates. After 48 hours of incubation, the medium was 
renewed with SPM for a further 24 hours of incubation, and then BSA-AGEs or non-
modified BSA were added for 5, 10, 30 and 120 minutes of incubation. Each condition was 
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performed in triplicate. After washing in cold PBS, all the intracellular proteins were 
extracted after lysing the cells with 120 µL/well of ice-cold radioimmunoprecipitation 
(RIPA) buffer (pH 7.5). The cell lysates were collected in cold eppendorf tubes then 
centrifuged at 20,000 g for 30 minutes at 4°C to get rid of the cell debris.For study of 
RAGE expression, the cells were treated with or without BSA or BSA-AGEs for 10 
minutes and 24, 48 and 72 hours of incubation. Each condition was performed in triplicate. 
The cells were then lysed with 80 µL/well of ice-cold (RIPA) buffer. The cell lysates were 
collected in cold eppendorf tubes then centrifuged at 20,000 g for 30 minutes at 4°C to get 
rid of the cell debris. 
Protein concentration of the intracellular and transmembrane proteins was determined 
using the Bradford protein assay and the samples (40 g of intracellular proteins and 100 
g of transmembrane proteins) were mixed with an equal volume of 2X Laemmli sample 
buffer, denatured by boiling in a water bath for 15 minutes then briefly centrifuged. 
Samples were separated along with pre-stained molecular weight markers using12% SDS-
PAGE. Proteins were electro blotted onto nitrocellulose membranes (1 hour) and the 
membranes were blocked for 1 hour at room temperature in TBS-Tween (pH 7.4) 
containing 1% BSA. Membranes were stained with the following primary antibodies 
diluted in the blocking buffer, overnight at 4°C on a rotating shaker: mouse monoclonal 
antibodies to phospho-extracellular signal-regulated kinase (p-ERK1/2, Tyr204 of ERK1, 
1:1000), rabbit polyclonal antibodies to ERK1/2 (1:1000) and mouse monoclonal 
antibodies to RAGE (1:1000) and mouse monoclonal antibodies to GAPDH. After washing 
five times for 10 minutes in TBS-Tween at room temperature, the filters were stained with 
either rabbit anti-mouse or goat anti-rabbit horse-radish peroxidase-conjugated secondary 
antibodies diluted in TBS-Tween containing 5% de-fatted milk (1:1000) for 1 hour at room 
temperature with continuous mixing. After a further 5 washes in TBS-Tween, proteins 
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were visualised using ECL chemiluminescent detection and analysed using GeneSnap 
software with Gene tool image analyser. 
 
2.7.8 Flow Cytometry Analysis 
The MDA-MB-231 cells (3 x 10
5 
/ mL) and MCF-7 cells (6 x 10
5 
/ mL) in 2 mL of 
complete medium were seeded in 6-well plates. After 24 hours of incubation, the medium 
was renewed with SPM for a further 24 hours of incubation, and then BSA-AGEs or non-
modified BSA were added for 10 minutes and 24, 48, 72 hours of stimulation at 37°C. 
Each condition was performed in triplicate. The cells were washed with PBS then the cells 
scraped to maintain intact the structure of the transmembrane protein RAGE. After 
centrifugation (300 g for 10 minutes), 10
6
 cells were re-suspended in 20 L of PBS then 20 
g/mL of mouse anti-RAGE antibody were added and the mixture kept on ice for 45 
minutes. The excess antibody was removed by washing the cells twice with PBS followed 
by centrifugation. After the second centrifugation, the cells were re-suspended in 20 L of 
PBS then 20 g/mL of rabbit monoclonal anti-mouse antibody-FITC were added and the 
mixture was kept on ice for 30 minutes. The RAGE expression level was measured using 
FAC Scan analysis software from FACS Calibur Flow Cytometer (Becton Dickinson). 
 
2.7.9 RAGE Neutralization 
To investigate whether BSA-AGEs act through RAGE, the cells were treated with anti-
RAGE antibody to neutralize all the RAGE receptors. Briefly, MDA-MB-231 cells (5 x 
10
4 
/ mL) in 1 mL of complete medium were seeded in 24-well plates. In pre-confluent 
cultures, the medium was renewed with SPM, and then 20 µg/mL anti-RAGE antibody or 
20 µg/mL IgG1 used as an isotype control were added to the medium. After 1 hour of 
incubation, the cells were treated with 100 µg/mL BSA-AGEs for 10 minutes stimulation 
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at 37°C. Each condition was performed in triplicate. Phospho-ERK1/2 expression was 
assessed by Western blotting as previously described.  
 
2.7.10 Kinexus Phospho-Protein Array Analysis 
The MDA-MB-231 cells (3 x 10
5 
/ mL) and MCF-7 cells (6 x 10
5 
/ mL) in 2 mL of 
complete medium were seeded in 6-well plates. After 48 hours of incubation, the medium 
was changed to SPM and after a further 24 hour-incubation, 100 g/mL BSA-AGEs or 
non-modified BSA were added and the cells incubated for 10 minutes at 37°C. To 
determine the protein expression profile of signalling pathways downstream of RAGE, 
Kinexus Bioinformatics (Vancouver, Canada) performed a phospho-protein array analysis 
(Kinetworks PhosphoSite Screen, KPSS-1.3). Protein samples (500 µg) from BSA-AGEs 
or non-modified BSA-stimulated and un-stimulated cells were extracted according to the 
manufacturer‟s instructions. The samples were used for a multi-immunoblotting assay 
based on SDS-polyacrylamide mini-gel electrophoresis with 20-lane multi-immunoblotters 
using different primary antibodies. The protein expressions were visualized by 
chemiluminescence and relative expression was determined by Kinexus and expressed in 
normalized counts per minute (C.P.M.). 
 
2.8 Statistical Analysis 
Results are expressed as mean ± standard deviation (SD). Experimental points were 
performed with a minimum of three independent experiments using freshly prepared 
solutions. An unpaired Student's t-test was used for comparison of two groups. A 
significant value are given as *: P < 0.05, **: P < 0.01 and ***: P < 0.001.  
0 
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Chapter 3. Effects of BSA-AGEs on Breast Cancer Cell Line 
MDA-MB231 
3.1 Introduction 
The glycation process leads to the formation of AGEs and plays a crucial role in the 
pathogenesis of diabetic complications and cancer. Several studies conducted both in vivo 
and in vitro, have shown a possible link between AGEs and cancer. However, the presence 
of AGEs identified in human cancer tissues, and their expression is distinctly varied 
between different types of tumors (Rojas, 2011). Moreover, many studies have investigated 
whether AGE-RAGE interaction is a potential stimulant for growth proliferation, migration 
and invasion in different human cell lines (Yamagishi et al., 2005). For example, one of 
the studies on gylceraldehyde-AGEs (glycer-AGEs) was shown to enhance malignancy of 
melanoma cells (Takino et al., 2010). However, the role of AGEs in breast cancer 
development is still not investigated. In this chapter, MDA-MB231 cell line was used, and 
this cell line is defined as tumors lacking estrogen receptor and shows remarkably high 
aggressive clinical behaviour. In order to study the impact of AGEs on MDA-MB231 cell 
line, several techniques have been performed to address the link between AGEs and breast 
cancer in vitro. Proliferation, migration and invasion are major techniques used in cellular 
and molecular biology in cancer. Moreover, RAGE expression was assessed and AGE-
induce signalling pathways through RAGE were investigated to identify new therapeutic 
targets for diabetic patients diagnosed with breast cancer.  
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3.1.1 Aim and objectives: 
The aim of this work is to examine the effects of BSA alone and BSA-AGE formation on 
breast cancer cell line MDA-MB231. 
 
1. To investigate the effects of different concentration of non-BSA and BSA-AGE glycated 
using different concentrations of methylglyoxal on cell proliferation, migration and 
invasion of MDA-MB231 breast cancer cell lines in vitro. 
2. To determine the changes in the cellular signalling after exposure to different 
concentrations of AGEs in vitro. 
3. To investigate the expression of RAGE-AGE involved in MDA-MB231 breast cancer 
cells following interaction with AGEs. 
 
3.1.2 Methods 
BSA or lysozymes were glycated as described in section 2.5.1. Crosslinked AGEs were 
assessed as described previously in section 2.5.6 .The formation of fluorescent AGEs was 
assessed by their characteristic fluorescence as mentioned in section 2.5.8. The effects of 
increasing concentrations of BSA-AGEs and non-modified BSA on cell proliferation are 
described in section 2.7.1. Cell viability was assessed according to section 2.7.2. Effect of 
BSA-AGEs on cell migration using wound-healing essay was described in detail in section 
2.7.3. Cell invasion was assessed using Matrigel as described in section 2.7.5. Western 
boltting was used to confirm the results as mentioned in section 2.7.7. Signalling pathway 
was investigated using RAGE neutralization as described in section 2.7.9. The effects of 
BSA-AGE on phosphorylation of protein were analysed by Kinexuse Bioinformatics as 
described in section 2.7.10. 
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3.2 Results 
3.2.1 The Effect of Different Concentrations of Methylglyoxal on AGE 
Formation in vitro 
The effect of varying concentration of methylglyoxal on glycation of lysozyme in vitro 
produced high amount of cross-linked AGEs within 3 days of incubation and caused the 
formation of AGEs Figure 3.1. These had molecular weight of approximately 42 kDa as 
indicated by molecular weight markers (lane M) in comparison with the lysozyme (lane a). 
The quantification of the effect of different concentrations of methyloglyoxal on cross-
linked AGE formation shows significant increase (P < 0.001) in Figure 3.2. The effect of 
different concentrations of methylglyoxal (0.01– 0.1 M) on formation of fluorescente is 
AGEs shown in Figure 3.3. 
 
 
 
 
 
 
 
 
 
Figure 3.1:  SDS-PAGE gel showing the effect of different concentrations of methylglyoxal 
on cross-linked AGE formation. Lysozyme (10 mg/mL) incubated alone (lane a) or in the 
presence of methylglyoxal (0.1 M lane b; 0.05 M lane c; 0.01 M lane d) respectively in 0.1 
M sodium phosphate buffer (pH 7.4) at 37°C for 3 days. Lane M, represent the molecular 
weight markers. The cross-linked AGEs were analysed using SDS-PAGE and stained with 
Coomassie brilliant blue. Each value represents the mean ± SD (n = 3). 
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Figure 3.2: The effect of different of concentrations of methylglyoxal on cross-linked AGE 
formation. The graph shows gradual increases with each concentration. Lysozyme (10 
mg/mL) incubated alone or in the presence of methylglyoxal (0.01M; 0.05M; 0.1 M) 
respectively. Each value represents the mean ± SD (n = 3). ***: P < 0.001.   
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Figure 3.3: Different concentration of methylglyoxal on fluorescent AGE formation in 
lysozyme-methylglyoxal system. Lysozyme (10 mg/ml) was incubated with different 
concentrations of methylglyoxal (0 - 0.1M) in 0.1 M sodium phosphate buffer of pH 7.4 at 
37 °C for 3 days. Each value represents the mean ± SD (n = 3). ***: P < 0.001.   
 
3.2.2 Effect of Period of Incubation on AGE Formation in vitro 
Adequate quantity of cross-linked AGEs was produced when BSA was allowed to react 
with glucose for varying incubation time during 15 days of incubation at 37ºC. The control 
sample contained BSA only (Figure 3.4, lane a). In comparison with the control, a gradual 
increase in the formation of the BSA-AGE with increasing time of glucose incubation, 
Figure 3.4 (lane b-f).  The effect of different incubation times on the formation of cross-
linked AGEs after scanning of this gel shows significant (p< 0.001) increase in comparison 
with BSA alon in Figure 3.5.  
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Figure 3.4: The effect of different incubation time on cross-linked AGE formation in 
the BSA-glucose system. Gel showing BSA (10 mg/ml) was incubated alone (lane a) or 
with glucose (0.5M) for different incubation time ( 3, 6 , 9 ,12, and 15 days ) (lane b-f) 
respectively in 0.1 M sodium phosphate buffer of pH 7.4 at 37 °C for 15 days. Lane M, 
represent the molecular weight markers. The cross-linked AGEs were analysed using SDS-
PAGE and stained with Coomassie brilliant blue. The result is a representative figure of at 
least three independent experiments.   
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Figure 3.5: The effect of different incubation time on cross-linked AGE formation in 
the BSA-glucose system. BSA (10 mg/ml) was incubated with glucose (0.5 M) in 0.1 M 
sodium phosphate buffer of pH 7.4 at 37 °C for 15 days. Each value represents the mean ± 
SD (n = 3) ***: P < 0.001.   
 
3.2.3 Effects of BSA-AGEs on MDA-MB-231 Cell Morphology, Proliferation 
and Viability 
Representative photomicrographs showing the MDA-MB-231cell morphology in untreated 
conditions (the control) and those treated with BSA-AGEs or non-modified BSA (Figure 
3.6 A-I). MDA-MB-231 breast cancer cell line cells, originally extracted from the tumor of 
breast epithelium tissue, displayed an epithelial-like morphology appearing as spindle 
shaped cells. At all concentrations used, BSA-AGEs and non-modified BSA did not 
change MDA-MD-231 cell morphology, compared to the control. As shown in Figure 3.6, 
BSA-AGEs induced a variation of the cell number in a dose-dependent manner, increasing 
then decreasing cell proliferation in a bell-shaped curve. The lowest concentration of BSA-
AGEs (25 g/mL) slightly but not significantly increased, while (50g/mL) BSA-AGE 
significantly enhanced by 1.5-fold (p<0.01) cell proliferation as compared to the untreated 
control cells and BSA-treated cells.  A peak of stimulation (2.0-fold increase) was reached 
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in the presence of 100 g/mL BSA-AGEs (p<0.001), whereas the highest concentration 
(200 g/mL) did not change the cell growth, compared to the untreated control cells and 
BSA-treated cells (Figure 3.7A). To estimate the specific effect of BSA-AGEs on cell 
proliferation, non-modified BSA was also tested. Compared to the control, BSA (50 
g/mL) slightly increased the cell proliferation (p<0.05) whereas no effect was observed 
with concentrations of BSA at 25, 100 and 200 g/mL (Figure 3.7A). Moreover, for each 
condition, the percentage of cell viability was determined by the trypan blue exclusion 
method and revealed a high percentage of viability, indicating the absence of cytotoxicity 
at the 25. 50, 100 g/mL concentrations of BSA-AGE and non-modified BSA used 
compared with control and compared as well with BSA. The percentage effects of viable 
cell numbers exposed to 200 μg/ml of BSA-AGEs and BSA only were reduced by 18 %, 
compared to the control (Figure 3.7B). 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: Effect of BSA-AGEs and non-modified BSA on the cell morphology of MDA-
MB-231 cells. Representative photomicrographs (x400 magnification of phase contrast 
microscopy) showing the MDA-MB-231 cell morphology in non-treated conditions 
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(control) (A) or treated either with 25-200 g/mL BSA-AGEs (B-E) or non-modified BSA 
(F-I) after 72 hours of incubation.  
 
 
Figure 3.7: Effect of BSA-AGEs and non-modified BSA on (A) proliferation and (B) 
viability of MDA-MB-231. (B) were determined using an automatic cell counter and the 
trypan blue exclusion method, respectively. Control indicates non-treated cells. The cells 
were non-treated or treated either with (25-200 g/mL) BSA-AGEs or 25-200 g/mL BSA 
for 72 hours. Results are presented as mean ± SD (n=3).  *: P < 0.05, **: P < 0.01 and ***: 
P < 0.001.   
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  3.2.4 Effect of BSA-AGEs on MDA-MB-231 Cell Migration  
The of the effects of BSA-AGEs on the migration of the breast cancer cell line MDA-MB-
231 may indicate how AGEs potentially contribute to tumour progression. MDA-MB-231 
cells were subjected to the wound-healing assay followed by a treatment with different 
concentrations (25-200 µg/mL) of BSA-AGEs or non-modified BSA. Representative 
photomicrographs show MDA-MB-231 cell migration under different conditions (Figures 
3.8 A-C). Compared to the untreated control and to non-modified BSA. BSA-AGEs at 25, 
50 and 100 g/mL concentration increased the number of migrated cells by nearly 2.0-fold 
with a p-value for 25g/mL (p<0.01) and 50-100 g/mL (p < 0.05) while at 200 g/mL, 
BSA-AGEs had no effect (Figure 3.8 D). On the distance of migration, BSA-AGEs 
significantly increased the cell migration in a dose-dependent manner with a peak of 
stimulation at 50 µg/mL 2.7 -fold increase (p< 0.01), compared to the control and 
compared with BSA-treated cells (Figures 3.8E). No change in a cell migration was 
observed with the highest concentration (200 g/mL) of BSA-AGEs (Figure 3.8D, E). 
Non-modified BSA (25-100 g/mL) had no effect on MDA-MB-231 cell migration 
(Figures 3.8 C and 3.8 D). However, 200 g/mL BSA decreased the number of migrated 
cells in comparison to untreated control cells (p <0.05) and BSA-treated cells (Figure 
3.8E). 
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Figure 3.8: Effect of BSA-AGEs and non-modified BSA on MDA-MB-231cell migration. 
Representative photomicrographs (x400 magnification) show the MDA-MB-231 cell 
migration measured from the wound edge (indicated by the arrow) after 24 hours of 
incubation in the (A) absence or (B) in the presence of 50μg/mL BSA-AGEs or (C) non-
modified BSA. (D) Shows the number of migrated cells, quantification of the number of 
migrated cells (black bars) and the distance of migration (grey bars) of MDA-MB-231 
cells treated in the aforementioned conditions. (E) the distance of migration of MDA-MB-
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231 treated in the conditions aforementioned. Results are presented as mean ± SD (n=3). *: 
P < 0.05, **: P < 0.01. 
 
3.2.5 Effect of BSA-AGEs on MDA-MB Cell 231 Invasion 
The effect of BSA-AGEs on the MDA-MB-231 cell invasion was estimated by counting 
the stained migrated cells, which passed across the porous membrane after invading the 
Matrigel™, a reconstituted basement membrane (Figure 3.9). Representative 
photomicrographs in Figure 3.9 A-C shows MDA-MB-231 cell invasion in untreated 
condition (Figure 3.9A), or treated either with 100 g/mL BSA-AGEs (Figure 3.9 B) or 
non-modified 100 g/mL BSA (Figure 3.9 C). Compared to untreated control cells, BSA-
AGEs modulated MDA-MB-231 cell invasion in a dose-dependent manner. The variation 
of MDA-MB-231 cell invasion induced by different concentrations of BSA-AGEs 
described a bell-shaped curve with a peak stimulation at 100 g/mL of BSA-AGE (2.39-
fold increase p< 0.01), while at 50 g/mL of BSA-AGE (2.35-fold increase p< 0.01) 
(Figures 3.9 D). Both were significantly increased compared to the control. The lowest 25 
g/mL and highest concentration 200 g/mL had no significant effect.  At all 
concentrations used (25-200 g/mL), no effect of non-modified BSA on MDA-MB-231 
cell invasion was observed (Figure 3.9 D).  
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Figure 3.9: Effect of BSA-AGEs and non-modified BSA on invasion of MDA-MB-231 
cells. Representative photomicrographs (x400 magnification) showing the effect of 
untreated MDA-MB-231 cells (A) and cells treated BSA-AGEs with 100 g/mL (B) or 
non-modified BSA with 100 g/mL (C) on invasion MatrigelTM assay for 24 hours of 
incubation. (D) The graph shows the number of invaded MDA-MB-231 cells treated with 
25-200 g/mL BSA-AGEs or non-modified BSA, compared to the untreated cells, the 
control. Results are presented as mean ± SD (n=3). **: P < 0.01.  
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3.2.6 Effects of BSA-AGEs on the Activities of Matrix Metalloproteinase  
Compared to the MMP-9 activity in untreated MDA-MB-231 cell-condition medium 
(control) assessed by gelatine substrate zymography, pro-MMP-9 activities produced by 
cells treated with 50 and 100 g/mL BSA-AGEs were significantly enhanced by 1.4-fold 
and 1.3-fold,  respectively (p<0.05) compared to the control (Figures 3.10 A and 3.10 B). 
A decrease of pro-MMP-9 activity was noticed when the cells were treated with 200 
g/mL BSA-AGEs (p<0.05), compared to the control. While active-MMP9 was also 
significantly enhanced at all concentrations by nearly 1.2-fold (p<0.05) at 25, and 200 
g/mL, by 1.6-fold (p<0.01) at 50 g/mL and by 2.2-fold (p<0.001) at 100 g/mL (Figures 
3.10 A and 3.10 B). At all concentrations of BSA-AGEs, used, no active MMP-2 was 
observed (Figure 3.10 C).  
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Figure 3.10: Effect of BSA-AGEs on MMP-9 and MMP-2 activities produced by MDA-
MB-231 cells during invasion Matrigel
TM
 assay. (A) Representative gelatine zymograhic 
analysis showing the MMP-9 and MMP-2 activities from different BSA-AGE-treated 
MDA-MB-231cell-condition media, compared to untreated cell-condition medium 
(control). The gels revealed gelatinolytic activities of pro- and active MMP-9 and pro-
MMP-2. (B) Shows the quantitative gelatinolytic activities of pro- and active MMP-9 and 
of (C) pro-MMP-2 expressed in relative activity calculated as a ratio to the control. 
(Results are presented as mean ± SD (n=3). *: P < 0.05, **: P < 0.01and ***: P < 0.001. 
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3.2.7 Effect of BSA-AGEs on RAGE Expression 
A time-course for the expression of RAGE was established by Western blotting after 
MDA-MB-231 cells in SPM treated with 100 g/mL BSA-AGEs were tested at different 
incubation times 10 min to 24 hours and 48 hours Figure 3.11 A1 shows that BSA-AGEs 
regulated RAGE protein expression in a time-dependent manner. Within 10 minutes 
incubation, a significant increase by 1.5-fold (p<0.01) of RAGE expression was detected 
compared to the basal level of RAGE expressed in untreated cells (Figure 3.11 A2). A 
peak of expression of RAGE was observed after 48 hours of incubation with BSA-AGEs 
2.0-fold increase (p<0.01) compare with the control 48 hours, (Figure 3.11 A2). The over-
expression of RAGE induced by BSA-AGEs in short incubation time (10 minutes) was 
also confirmed using flow cytometry analysis revealing a significant increase of RAGE 
expressed on the cell surface (Figure 3.11 B1 and B2). 
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Figure 3.11: Time course of RAGE expression in MDA-MB-231 cells treated with BSA-
AGEs. (A1) Representative Western blot analysis showing the effect of 100 μg/mL BSA-
AGEs on RAGE expression in MDA-MB-231 cells after 10 minutes, 24 hours, and 48 
hours of incubation, compared to untreated cells (control). (A2) shows the relative 
expression of RAGE calculated as a ratio to GAPDH expression, the loading control. B1 
and B2 Photomicrographs showing a representative FACS analysis of the up-regulation of 
RAGE expression induced by 100 g/mL BSA-AGEs after 10 minutes of incubation and 
IgG1 was used as an isotype control. Each value represents as mean ± SD (n = 3).  **: P < 
0.01. 
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3.2.8 BSA-AGEs Induced p-ERK1/2 Expression in MDA-MB-231 Cells 
through RAGE 
To investigate whether the BSA-AGEs might induced cell signalling based upon the 
incubation time, a Western blot analysis was carried out to examine the expression of the 
phospho-extracellular-signal regulated kinase-1/2 (p-ERK1/2) in MDA-MB-231 cells 
treated with 100 g/mL BSA-AGEs for 5, 10, 30 and 120 minutes (Figure 3.12 A). BSA-
AGEs increased the expression of p-ERK-1/2 in the cells after 5 minutes of incubation. 
The maximum BSA-AGEs-induced pERK-1/2 expression was reached at 10 minutes of 
incubation then slightly decreased at 30 minutes, finally disappeared after 120 minutes of 
exposure (Figure 3.12 A). To study the effect of different concentrations of BSA-AGEs on 
p-ERK1/2 expression, the cells were treated with or without 25-50-100 and 200 µg/mL of 
BSA-AGEs or non-modified BSA for 10 minutes of incubation (Figure 3.12 B). Compared 
to untreated control cells, BSA-AGEs tested at different concentrations (25-50-100 and 
200 µg/mL) modulated p-ERK1/2 expression in a dose-dependent manner with a peak of 
stimulation of 1.7 and 2.75 -fold for p-ERK1 and p-ERK2, respectively, (p<0.01) with 100 
g/mL of BSA-AGEs (Figure 3.12 B). Non modified BSA significantly increased the 
phosphorylation of p-ERK1/2 at lower concentrations (25-50 g/ml) while at higher 
concentrations (100-200 g/ml) non-modified BSA had no  phosphorylation of p-ERK1/2 
as compared to the control (Figure 3.12 B).  
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Figure 3.12: Effect of BSA-AGEs on phospho-ERK1/2 expression in MDA-MB-231 cells. 
(A) Representative Western blot analysis showing the variation of p-ERK1/2 expression 
induced by 100 μg/mL BSA-AGEs after different incubation times varying from 5 to 120 
minutes, compared to untreated control cells. (B) Representative Western blot analysis 
showing the effect of 25-200 g/mL BSA-AGEs or non-modified BSA on p-ERK1/2 
expression, compared to untreated cells. (C) Relative expression of p-ERK1/2 calculated as 
a ratio to the total ERK1/2 (t-ERK1/2), the loading control. Each value represents the mean 
± SD (n = 3). *: P < 0.05 and **: P < 0.01. 
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To check whether BSA-AGEs mainly induce signalling pathways including p-ERK1/2 
activation in MDA-MB-231 through its major receptor RAGE, the cells were pre-treated 
with an anti-RAGE antibody blocking all the RAGE receptors or with an isotype control 
IgG1 (Figure 3.13 A). The isotype control did not affect BSA-AGEs-induced p-ERK1/2 
over-expression; while there was no change in p-ERK1/2 expression in the cells treated 
with 100 μg/mL BSA-AGEs after blockade of RAGE by anti-RAGE neutralizing antibody 
when compared to basal level of p-ERK1/2 in untreated cells (Figure 3.13 B).
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Figure 3.13: Effect of RAGE neutralization on BSA-AGEs-induced phospho-ERK1/2 
expression in MDA-MB-231 cells. (A) Representative Western blot analysis showing the 
loss of BSA-AGE-induced p-ERK1/2 over-expression after the blockade of RAGE 
function utilising a neutralising blocking anti-RAGE antibody, compared to untreated cells 
(control) and an isotype control IgG1. (B) Relative expression of p-ERK1/2 calculated as a 
ratio to the total ERK1/2 (t-ERK1/2), the loading control. Value represents the mean ± SD 
(n = 3). **: P < 0.01.  
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3.2.9 Effects of BSA-AGEs on the Expression of Phosphorylated Proteins  
To investigate the potential downstream phosphorylated proteins of BSA-AGEs/RAGE 
signalling pathways, the whole cell lysates from untreated MDA-MB-231 cells (Figure 
3.14 A1) and from cells treated with 100 g/mL BSA-AGEs (Figure 3.14 A2) or treated 
with 100 g/mL non-modified BSA (Figure 3.14 A3) for 10 minutes were analysed using 
the phospho-protein array KPSS-1.3 which contains 35 phospho-proteins including p-
ERK2 (Figure 3.14 A). Consistent with previous Western blot data (Figure 3.12 C), the 
bio-informatic analysis of the phspho-protein array showed that BSA-AGEs caused a 3.0-
fold increase of p-ERK2 expression (Figure 3.14 B). In addition, BSA-AGEs mainly 
induced the over-phosphorylation of the ribosomal protein serine S6 kinase (p70S6K)-beta 
1 (25.4-fold increase), of the signal transducer and activator of transcription (STAT)-3 
(8.0-fold increase), MAPK p38 and glycogene synthase-serine kinase (GSK)-3 (5.6-fold 
and 3.2-fold, respectively), and MAPK/ERK protein-serine kinase 1/2 (4.6-fold increase), 
compared to untreated control cells (Figure 3.14 B). The phosphorylation of proteins acting 
as transcription factors such as c-Jun including its kinase JNK were increased (2.0-fold) in 
BSA-AGE-treated cells, compared to untreated cells. The phosphorylation of tumour-
suppressor protein named retinoblastoma-associated protein-1 (pRb) was also increased 
(2.6-fold) in BSA-AGE-treated cells, compared to untreated cells. While BSA-AGEs 
enhanced the expression of most of the phospho-proteins, the cell treatment with non-
modified BSA displayed a similar profile of phospho-protein expressions as untreated 
control cells (Figure 3.14). 
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Figure 3.14: Effect of BSA-AGEs and non-modified BSA on phospho-protein expression 
in MDA-MB-231. (A) The multi-immunoblotting showing the expression of 35 phospho-
proteins in untreated (A1) MDA-MB-231 cells, cells treated with 100 g/mL BSA-AGEs 
(A2) or 100 g/mL non-modified BSA (A3) for 10 minutes. (B) Relative expression of the 
relevant phospho-proteins expressed in counts per minute and calculated as a ratio to the 
untreated control cells. Value represents the mean ± SD (n = 3). 
 
 
81 
 
3.3 Discussion 
Diabetes and cancer are of major concern because of their high incidences in Western 
countries and more recently in developing countries. A growing body of epidemiological 
evidence has begun to indicate a molecular link between diabetes and breast cancer 
(Tesrasová et al, 2007; Logsdon et al, 2007). Moreover, in diabetic patients, the most 
circulating and abundant protein-derived AGE formed from a non-enzymatic oxidation of 
glucose is serum glycated albumin (Furusyo and Hayashi, 2013); furthermore, in patients 
with breast cancer, serum concentrations of AGEs were higher than in healthy controls 
(Tesrasová et al, 2007). To date, the biological effects of glycated albumin on human 
breast cancer cells have been poorly described. 
 
This study examined for the first time the in vitro biological effects of different 
concentrations of BSA-derived AGEs on the invasive breast cancer cell line MDA-MB-
231, compared to non-modified BSA that is commonly used as molecular model (Khan et 
al, 2013). We showed that BSA-AGEs at 100 µg/mL increased MDA-MB-231 cell 
proliferation, migration and invasion through growth factor reduced Matrigel™ (a 
reconstituted basement membrane). Cell invasion is a critical step during tumour 
progression because the basement membrane represents the last barrier for the cancer cells 
to reach the blood circulatory system and be disseminated via metastasis (Martin et al, 
2000; Zijl et al, 2011). The effects of BSA-AGEs on elevated cell invasion might be 
associated with an enhancement of MMP-9 gelatinase activity. Furthermore, BSA-AGEs 
increased the expression of the main receptor for AGEs (RAGE) and induced an 
overexpression of phospho-ERK1/2 through RAGE. A wider investigation of BSA-AGE-
induced signalling pathways in MDA-MB-231 cells highlighted the over-phosphorylation 
of key proteins involved in the control of protein synthesis and cell survival, including 
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p70S6K1 and STAT-3, compared to untreated cells. Throughout the study, non-modified 
BSA had almost no biological effects on MDA-MB-231 cells.  
 
This present study showed that BSA-AGEs increased, in a dose-dependent manner, MDA-
MB-231 cell proliferation, migration and invasion, while non-modified BSA had mostly no 
effect but a slight stimulatory effect on cell proliferation at 50g/mL, this negligible 
mitogenic effect of non-modified BSA is correlated to the induction of ERK1/2 
phosphorylation observed at short incubation time (10 minutes). In our present study and 
also reported by Chung and colleagues (2010), using tubular epithelial cells in similar 
conditions (Chung et al., 2010). The bell-shaped curve is indicative of a bivalent bridging 
mechanism describing the cell response through the dimerization /oligomerization of 
specific cell-surface receptors after binding with the ligand (Posner et al, 1998). A recent 
study provides insights into the factors including glycation reagent like methylglyoxal and 
the RAGE structure that influence AGEs-RAGE binding (Indurthi et al., 2012). 
Throughout this present study, the maximal cell response was obtained with 50 and 100 
g/mL BSA-AGEs, which seem to correspond to the optimal oligomerization of the AGE 
receptor such as RAGE to induce the maximal signalling stimulation. Recently, using an 
epitope-defined monoclonal antibody that specifically recognises oligomerization, Xu and 
colleagues (2013) demonstrated the importance of RAGE oligomerization for the 
formation of active signalling complex. Therefore, the loss of the cell response seen at high 
concentrations of BSA-AGEs may be explained by the impediment of AGE receptor 
oligomerization (Xu et al, 2013). Recently, using siRNA technology, RAGE has been 
demonstrated to play a critical role in the growth of human breast cancer cell lines, 
including MDA-MB-231 (Radia et al, 2013). Throughout most of the studies on BSA-
AGEs including this present investigation, the biological effects of BSA-AGEs were 
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compared to native non-modified BSA and it showed no significant biological effect on 
MDA-MB231 (Yu et al., 2013; Shi et al, 2013). Mainly used as an anti-inflammatory or 
anti-cancerous drug carrier with the benefit to prolong the half-life of the drug, native 
globular BSA even bound on the cell surface rarely triggers specific transduction signalling 
like BSA-AGEs (Arkin et al, 2012; Rasheed et al, 2011; Shi et al, 2013). Therefore, our 
results suggest that the mode of action of BSA-AGEs is dependent on signalling pathways 
mediated via RAGE rather than BSA-mediated pathways. 
Matrix metalloproteinases (MMP) are enzymes considered as important regulators in 
tumour-cell invasion. In particular, MMP-2 and MMP-9, also called gelatinases, play a key 
role in the degradation of type IV collagen of the basement membrane, thus contributing to 
tumour invasion and metastasis (Klein et al, 2004). The results of this chapter also showed 
that BSA-AGEs enhanced the motility and invasive capacity of the MDA-MB-231 cells 
with increased MMP-9 gelatinase activity whereas MMP-2 gelatinase activity was not 
changed. Non-modified BSA had no effect on both MMP activities. It is known that 
invasion and metastasis are key cellular processes resulting in tumour progression; they are 
the hallmarks of cancer malignancy. Cancer cell metastasis represents the main cause of 
treatment failure and death in cancer patients (Abe et al, 2004). Contributing to metastasis, 
cancer cells degrade the extra cellular matrix by the production and secretion of MMPs 
which allowing their cell migration and invasion across the connective tissue and the 
basement membrane to finally reach the blood circulation, the main route of tumour 
dissemination towards vascularized organs. A recent study showed that human lung 
adenocarcinoma cells treated with glyceraldehyde-AGEs for 48 hours had promoted cell 
migration and invasion across Matrigel™ with the enhancement of MMP-2 activity but not 
MMP-2 mRNA (Takino et al, 2010). MMP-9 from body fluid has proved a putative 
biomarker in metastatic breast cancer (Noh et al, 2012). Hallet and colleagues (2013) 
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targeted MMP-9 mRNA in a mouse model using anti-MMP-9 DNAzyme transfected into 
MDA-MB-231 cells, and they reported decreased breast cancer metastasis and they 
confirmed the key role of MMP-9. Furthermore, using a murine macrophage cell line, 
AGEs have been demonstrated to mainly regulate MMP-9 production via RAGE and 
through activation of ERK1/2, p38 MAPK and NF-B (Hallett et al, 2013; Zhang et al, 
2011). Therefore, our results suggest that BSA-AGEs might promote breast tumour 
progression and metastasis by increasing cancer cell migration, invasion and MMP-9 
activity. During treatment with BSA-AGEs, the breast cancer MDA-MB-231 cells became 
more sensitive to AGE, which is characterized by the up-regulation of RAGE expression 
from 10 minutes up to 48 hours of incubation. Shi and colleagues (2013) showed that 
AGEs up-regulate RAGE expression in various tissues reaching a maximum after a 24-
hour treatment, facilitating the AGE-RAGE response by forming a positive feedback loop 
(Shi et al, 2013). Thus, these results suggest that RAGE up-regulation induced by BSA-
AGEs may contribute to the increased cell response assessed in proliferation, migration 
and invasion. 
The study of the signalling pathways induced by BSA-AGEs was analysed after a-10 
minute BSA-AGEs treatment on MDA-MB-231 cells. The optimal signal transduction 
time was based on the increased expression of phospho-ERK1/2, a phospho-protein widely 
known to play a central role in most of the cellular responses including cell proliferation, 
migration and invasion. It was demonstrated that BSA-AGEs induced ERK1/2 expression 
through RAGE. After neutralization of the receptor using a specific monoclonal antibody. 
BSA-AGEs failed to stimulate p-ERK1/2 expression. Thus, this result eliminates the 
involvement of other AGE receptors such as CD36, scavenger receptors class a type II, 
class B type I and AGE receptors 1, 2 and 3 that are mainly implicated in the detoxification 
of AGEs rather than in signalling processes (Marsche et al, 2007).  
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Furthermore, non-modified BSA did not change the phospho-proteome profile of MDA-
MB-231 cells compared to untreated cells, BSA-AGEs concomitantly increased the 
phosphorylation of p70 ribosomal protein serine S6 kinase beta 1 (p70 S6K1), the signal 
transducer and activator of transcription (STAT)-3, p38 MAPK, glycogen synthase kinase 
(GSK)-3 and of MAPK/ERK protein-serine kinase 1/2 (MKK1/2), which are mainly 
involved in the control of protein synthesis, cell cycle progression, cell survival and 
ERK1/2 activation, respectively (Sato et al, 2011; Uehara et al, 2012; Kim  et al, 2013; Ko 
et al, 2011). Further, the p70 ribosomal S6K1 has been demonstrated to play a central role 
in tumour growth by regulating insulin pro-angiogenic effects and protein synthesis (Zhou 
et al., 2007; Dennis et al., 2012). Constitutively activated STAT proteins, which are critical 
in the regulation of cell cycle and cell growth, are found in various types of tumours 
including breast cancer (Chung et al., 2013). However, there is still limited information 
about its role in cancer. Previous studies have reported the p38 MAPK as a central kinase 
in a common intracellular signalling pathway that plays an essential role in human breast 
cancer cell migration and invasion by modulating the expression and activity of MMPs 
(Wang et al., 2013). Furthermore, several lines of evidences suggest a link between p38 
MAPK activation and MMP-9 expression (Ranaivo et al., 2012). Overall, our results 
suggest that BSA-AGEs mainly stimulated MDA-MB-231 cells in terms of protein 
synthesis machinery and survival ability. Among these over- expressed phospho-proteins, 
using pharmacological inhibitors of GSK-3 and of p38 MAPK in MDA-MB-231 cells and 
in a model mouse of breast cancer, some studies have lately demonstrated their key 
requirement in breast cancer development (Sukhtankar et al, 2011; Kim et al, 2013). In 
addition, targeting p70S6K1 gene expression by micro-RNA 145 could inhibit tumour 
growth (Xu et al, 2012). Thus, showing for the first time this distinctive over-expression of 
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phosho-p70S6K1 induced by BSA-AGEs, targeting phospho-p70S6K1 expression might 
prevent the progression and the development of breast cancer in diabetic patients.  
In conclusion, we showed for the first time the dose-dependent stimulatory effects of BSA-
AGEs on an invasive and non-hormone-dependent breast cancer cell line MDA-MB-231, 
regarding cell proliferation, migration and invasion with an enhancement of MMP-9 
activity, compared to inactive non-modified BSA. Among the phospho-proteins involved 
in BSA-AGE-induced signalling pathways, we also highlighted a concomitant increase of 
the phosphorylation of ribosomal protein serine S6 kinase beta 1, which might be a new 
biomarker of the invasive subtype of the breast cancer and a promising targeted drug to 
prevent development and progression of the breast cancer in diabetic patients. 
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Chapter 4. Effects of BSA-AGEs on Breast Cancer Cell Line 
MCF-7 cells 
4.1 Introduction 
AGE plays an important role in many pathological conditions including prostate cancer, 
ovarian cancer and colon cancer. Breast cancer is considered as the second leading cause 
of death in women, and may result from alteration of the normal cells, which causes 
chronic inflammation that promotes mammary tumours. Chronic inflammation is the 
underlying mechanism in breast cancer development and numerous studies have 
determined that inflammation can be induced due to accumulation of AGEs.  Breast cancer 
is categorised into several sub-types according to immunohistochemistry markers. MCF-7 
hormone-dependent breast cancer cell line is widely used in the investigation of tumour 
biology and the molecular biology of oestrogen action. MCF-7 is less aggressive, and has a 
better prognosis than other types. This cell line was isolated from a 69- year- old Caucasian 
in 1970, and known as malignant adenocarcinoma in a pleural effusion. Band and Sager 
(1989) have reported that MCF-7 cells were difficult to grow in culture due to their 
estrogen sensitivity.  After investigating the effects of BSA-AGEs on MDA-MB-231 cells, 
the same studies were applied to MCF-7 cells, to described differences between MCF-7 
and MDA-MB-231 cells, in terms of morphology, phenotypes and signalling pathways 
(Kirschmann et al, 2002; Gupta and Tikoo, 2013).  
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4.1.1 The Aim and objectives: 
The aim of this work is to examine the effects of BSA alone and BSA-AGE formation on 
breast cancer cell line MCF-7. 
The objectives are:  
1.  To investigate the effects of different concentration of BSA and BSA-AGE on cell 
proliferation migration and invasion of MCF-7 breast cancer cell line in vitro. 
2. To determine the changes in the cellular signalling after exposure to different 
concentrations of AGE in vitro. 
3. To investigate the expression of RAGE-AGE involved in the MCF-7 breast cancer cell 
line.  
4. To investigate the effect of BSA-AGEs on downstream phosphorylation proteins in 
MCF-7 cell. 
 
4.1.2 Methods: 
Studies on the effects of increasing concentrations of BSA-AGEs and non-modified BSA 
on cell proliferation are described in section 2.7.1. Cell viability was assessed according to 
section 2.7.2. BSA-AGE on cell migration using Boyden chamber assay was described in 
section 2.7.4. Cell invasion was assessed using Matrigel as described in section 2.7.5 and 
the results confirmed by using gelatine zymography as outlined in section 2.7.6. Western 
boltting was used to confirm the results as mentioned in section 2.7.7. Signalling pathway 
was investigated using RAGE neutralization studies as described in section 2.7.9. The 
effects of BSA-AGE on phosphorylation of protein were analysed by Kinexuse 
Bioinformatics as described in section 2.7.10. 
89 
 
4.2 Results 
4.2.1 Effects of BSA-AGEs on MCF-7 Cell Morphology, Proliferation and      
Viability 
Representative photomicrographs (Figure 4.1) show the cobblestone-like morphology of 
the MCF-7 cells with the apparition of clusters at the end of the treatment. The addition of 
BSA-AGEs or non-modified BSA did not change the cell morphology observed in non-
treated conditions (Figure 4.1). As shown in Figure 4.2.A, BSA-AGEs affected MCF-7 
proliferation in a dose-dependent manner, with peak stimulation in the presence of 50 
g/mL BSA-AGEs (26% increase, p< 0.001), and 100 g/mL BSA-AGEs (20% increase, 
p<0.001) compared to the untreated control cells. BSA-AGEs at the lowest concentration 
(25 g/mL) had no effect on MCF-7 cell proliferation whereas a significant inhibition of 
the cell growth was observed (17.0% decrease, p < 0.001) at the highest concentration (200 
g/mL) compared to untreated control cells. At all concentrations used (25-200 g/mL), 
non-modified BSA had no effect on MCF-7 cell proliferation (Figure 4.2.A). Moreover, 
the percentage of cell viability was determined by the trypan blue exclusion method. BSA-
AGEs and BSA at all used concentrations produced similar patterns for percentage of 
viable cells as shown (Figure 4.2B). At concentrations of 50, and 100 g/mL, BSA-AGE 
and BSA did not affect cell viability compared to untreated control cells. However, at the 
highest concentration used (200 g/mL), BSA-AGE reduced cell viability by 15% 
(p<0.05). At the lowest concentration used (25 g/mL), BSA-AGE increased the viability 
by 14% (p<0.05). 
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Figure 4.1: Effect of BSA-AGEs and non-modified BSA on MCF-7 cell morphology 
Representative photomicrographs (X400 magnification of phase contrast microscopy) 
showing the MCF-7 cell morphology in non-treated conditions control (A) or treated either 
with 25-200 g/mL BSA-AGEs (B-E) or non-modified BSA (F-I) after 72 hours of 
incubation. At all conditions, BSA-AGEs and BSA did not change the cobblestone-like 
morphology of MCF-7 cells which formed clusters.  
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Figure 4.2: Effect of BSA-AGEs and non-modified BSA on (A) cell proliferation and 
(B) viability of MCF-7 cells. Cell viability was determined using an automatic cell 
counter and the trypan blue exclusion method, respectively. The cells were non-treated or 
treated either with 25-200 g/mL BSA-AGEs or BSA for 72 hours.  Results are presented 
as mean ± SD of three independent experiments. (*) and (***) signify a statistically 
significant difference (p < 0.05, and p < 0.001), compared with control and BSA-treated 
cells.  
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4.2.2 Effects of BSA-AGEs on MCF-7 Cell Migration  
Due to the formation of clusters by MCF-7 cells, the Boyden chamber system was used to 
assess the effect of BSA-AGEs on MCF-7 cell migration. MCF-7 cells were incubated in 
SPM in the presence or absence of different concentrations (25, 50, 100, 200 g/mL) of 
BSA-AGEs or non-modified BSA for 24 hours before the migrated cells were counted. 
Figure 4.3A-C showed the representative photomicrographs of the stained MCF-7 cells, 
which passed across the porous membranes of Boyden chambers. BSA-AGEs at 50 g/mL 
and 100 g/mL significantly increased cell migration by 1.7 -fold (p < 0.001) and 2.3 -fold 
(p < 0.001), respectively, as compared to the control (Figure 4.3). At the lowest (25 
g/mL) and the highest (200 g/mL) concentrations used, BSA-AGEs did not significantly 
change the number of migrated cells, as compared to the untreated control cells. At all 
concentrations, used non-modified BSA had no effect on MCF-7 cell migration when 
compared to untreated control cells. 
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Figure 4.3: Effect of BSA-AGEs and non-modified BSA on MCF-7 cell migration. 
Representative photomicrographs (x400 magnification) showing the effect of (A) untreated 
MCF-7 cells and (B) cells treated with 100 g/mL BSA-AGEs or (C) non-modified BSA 
on cell migration using the Boyden chamber method for 24 hours. Stimulated cells, which 
had migrated across the porous membrane, were stained with Giemsa dye for counting. (D) 
Shows the number of migrated MCF-7 cells. Results are presented as mean ± SD of three 
independent experiments. Results are presented as mean ± SD of three independent 
experiments. (**) and (***) signify a statistically significant difference (p < 0.01 and p < 
0.001), compared with the control and BSA-treated cells. 
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94 
 
4.2.3 Effects of BSA-AGEs on MCF-7 Cell Invasion and MMP-2/-9 Activities 
In contrast to the highly aggressive MDA-MB-231 cells, the MCF-7 cells are well known 
for their low invasive and metastatic potential (Kirschmann et al, 2002). In this study, 
MCF-7 cells were unable to invade and pass across the Matrigel™ covered porous 
membranes of Boyden chambers in the presence or absence of different concentrations (25, 
50,100 and 200 g/mL) of BSA-AGEs or non-modified BSA. There were no stained cells 
observed under microscope.  
 
The MMP-2 and MMP-9 activities were assessed using gelatine zymography. The cell- 
medium was collected after the MCF-7 invasion assay in which cells were incubated in the 
presence or absence of different concentrations of BSA-AGEs or non-modified BSA for 24 
hours.  As expected from the absence of cell invasion, at all conditions used, BSA-AGEs 
and non-modified BSA did not activate MMP-2 and MMP-9, which was indicated by the 
absence of the  lysis of gelatine, on the zymogram gel (Figure 4.4). 
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Figure 4.4: Effect of BSA-AGEs on MMP-9 and MMP-2 activities produced by MCF-
7 cells during invasion Matrigel
TM
 assay. The gel representative gelatine zymograhic 
analysis of MCF-7 cells showing the absence of MMP-9 and MMP-2 activities from 
different concentrations of BSA-AGE (25, 50, 100 and 200 g/mL), compared to untreated 
cell-condition medium (control) after 24 hours. The gel has not showed any activation of 
MMP. 
 
4.2.4 The Effects of BSA-AGEs on the Expression of p-ERK1/2 in MCF-7 Cells 
To study the effect of different concentrations of BSA-AGEs on p-ERK1/2 expression or 
untreated control for 10 minutes in MCF-7 cells. The effects of BSA-AGEs on the 
expression of p-ERK1/2 were assessed by Western blotting (Figure 4.5). The results 
showed that BSA-AGEs modulated the expression of p-ERK1/2 in a dose-dependent 
manner (Figure 4.5A1). The addition of 50g/mL BSA-AGEs induced the expression of 
p-ERK1 by1.4-fold (p<0.05), wheres p-ERK2 expression was not changed when compared 
to the basel level of p-ERK1/2 expression in untreated control cells (Figure 4.5A2). The 
maximum stimulation was at 100 g/mL BSA-AGEs, which resulted in a 2.2-fold increase 
of p-ERK1 (p<0.001) expression and 1.5-fold (p<0.01) increase of p-ERK2 expression, 
compared to untreated cells. At the lowest and highest concentrations used (25 and 200 
BSA-AGEs (µg/ mL) 
Control 25 50 100 200 
 
pro-MMP9 
MMP9 
pro-MMP2 
MMP2 
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g/mL), BSA-AGEs mostly showed an inhibitory effect with  approximately 30% decrease 
of p-ERK1/2 expression by 25 g/mL of BSA-AGEs and 20% (p<0.05) decrease of p-
ERK1 expression by 200 g/mL of BSA-AGEs when compared to the untreated control 
cells (Figure 4.5A2). At all the concentrations used (25, 50, 100 and 200 g/mL) non-
modified BSA had no significant effect on p-ERK1/2 expression in MCF-7 cells (see 
Figure 4.5B1 for 100 g/mL BSA), compared to untreated control cells. The t-ERK was 
used as a loading control (Figure 4.5A). 
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Figure 4.5: Effect of BSA-AGEs on-ERK1/2 expression in MCF-7 cells. (A1) 
Representative Western blot analysis, showing the variation of p-ERK1/2 expression 
induced by 25-200 g/mL BSA-AGEs after 10 minutes incubation, compared to untreated 
control cells, in lane C. The graph (A2) shows the relative expression of p-ERK1/2 
calculated as a ratio to the total ERK1/2 (t-ERK1/2), the loading control. (B1) 
Representative Western blotting analysis. (B2) Relative expression of p-ERK1/2 calculated 
as a ratio to the total ERK1/2 (t-ERK1/2), the loading control. Results are presented as 
mean ± SD (n=3). ).*: P < 0.05, **: P < 0.01, ***: P < 0.001. 
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4.2.5 The Effects of BSA-AGEs on RAGE Expression in MCF-7 Cells 
A time-course of the expression of RAGE in MCF-7 cells following the treatment of 100 
g/mL BSA-AGEs was established by Western blotting. Figure 4.6 shows that BSA-AGEs 
up-regulated RAGE protein expression in a time-dependent manner. In the untreated 
conditions, RAGE expression was enhanced with the incubation time due to a quick 
synthesis of RAGE protein Figure 4.6A. Compared to the basal expression of RAGE in 
untreated cells, RAGE expression was increased in MCF-7 cells treated with 100 g/mL 
BSA-AGE by 2.8-fold (p<0.001) after 10 minutes incubation time. On treating the cells 
with 100 g/mL BSA-AGEs, the expression of RAGE was highly increased by 3.0-fold 
(p<0.001) at 24 hours compared to untreated cells (control) nd by 2.3- fold (p<0.001) after 
48 hours incubation time (Figure 4.6B).  
 
  
100 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Time course of RAGE expression in MCF-7 cells treated with BSA-AGEs. 
(A) Representative Western blot analysis showing the effect of 100 μg/mL BSA-AGEs on 
RAGE expression in MCF-7 cells after 10 minutes, 24 hours, and 48 hours of incubation, 
compared to untreated cells (control). (B) Relative expression of RAGE calculated as a 
ratio to GAPDH expression, the loading control. Results are presented as mean ± SD 
(n=3). ***: P < 0.001. 
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4.2.6. The Effects of BSA-AGEs on Phosphorylation in MCF-7 Cells 
4.2.6.1 BSA-AGE Induced Phosphorylation of MAPK/ERK Protein-Serine 
Kinase 1/2 and cAMP Response Element Binding Protein 1 (CREB1) 
To investigate downstream phosphorylated proteins of BSA-AGEs/RAGE signalling 
pathways, the whole cell lysates from untreated MCF-7 cells (Figure 4.7A1), or from cells 
treated with 100 g/mL BSA-AGEs (Figure 4.7A2) or 100 g/mL non-modified BSA 
(Figure 4.7A3) for 10 minutes were analysed using the phospho-protein array KPSS-1.3 
(Figure 4.7A). The bio-informatics analysis of the immuno-blots showed that BSA-AGEs 
caused 1.17- and 1.3-fold increase of p-ERK1 and p-ERK2 expression respectively, as 
compared to the untreated control cells (Figure 4.7B). Compared to untreated control cells, 
BSA-AGEs increased by 2.04-fold phospho-protein expression of MAPK/ERK protein-
serine kinase 1/2, which is an upstream kinase activator of p-ERK1/2 (Figure 4.7B). 
Compared to untreated control cells, BSA-AGEs also increased by 1.98-fold phospho-
protein expression of cAMP response element binding protein 1 (CREB1), which was 
lately reported to be associated with breast cancer development (Son et al, 2010) (Figure 
4.7B). In addition, non-modified BSA also increased by 50% phospho-protein expression 
of  CREB1 and MAPK/ERK protein-serine kinase1/2 as compared to untreated cells 
(Figure 4.7B).  
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Figure 4.7: Up-regulatory effect of BSA-AGEs on phospho-protein expression in 
MCF-7 using phospho-protein-array. (A) The multi-immunoblotting showing the 
expression of 35 phospho-proteins in (A1) untreated MCF-7 cells, (A2) cells treated with 
100 g/mL BSA-AGEs or non-modified BSA (A3) after 10 minutes of incubation. (B) 
shows the relative expression of the relevant overphosphorylation of CREB1, 
MKK1/2,/ERK1 and ERK2 expressed in counts per minute and calculated as a ratio to the 
untreated control cells. 
 
 
103 
 
4.2.6.2 BSA-AGEs Down-Regulated the Phosphorylation of Protein-Serine kinase 
C (PKC) Isoforms, Mitogen and Stress-Activated Protein-Serine kinase 1 (Msk1) 
and Adducin   
Phosphorylation of protein-serine kinase C (PKC) isoforms such as PKCPKC/2, 
PKC, and PKChave been described to play different roles in breast cancer progression 
(Urtreger et al, 2012). The phospho-protein array analysis demonstrated that  BSA-AGEs 
induced a down-regulation of the phosphorylated PKC by 20%, while non-modified BSA 
up-regulated PKC phospho-protein expression by 1.75-fold as compared to the untreated 
control cells. Treatment with BSA-AGEs also caused a decrease in the phosphorylated 
PKCPKC/2 (60%), and PKCand PKC(60%). The phosphorylation 
of mitogen and stress-activated protein-serine kinase 1 (Msk1) was also assessed. Mski is 
an activated downstream protein of ERK1/2 and of p38 pathways and is involved in cell 
survival, proliferation and differentiation. The phosphorylation of Msk1 was down-
regulated by 40% in MCF-7 cells after cell treatment with BSA-AGE treatment (Figure 
4.8). The phosphorylation of adducin a cytoskeleton protein, which dissociates from F-
actin and spectrin during cell migration, was down-regulated by 60% in MCF-7 cells after 
BSA-AGE treatment, as compared to the untreated control cells. However, the MCF-7 cell 
treatment with non-modified BSA induced a level of expression slightly higher than BSA-
AGEs-down-regulated phospho-protein expression of PKCPKC/2, PKC, ADD1 and 
Msk1.  
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Figure 4.8: Down-regulatory effect of BSA-AGEs on phospho-protein expression in 
MCF-7 using phospho-protein-array. (A) Multi-immunoblotting showing the expression 
of 35 phospho-proteins in (A1) untreated MCF-7 cells, (A2) cells treated with 100 g/mL 
BSA-AGEs or (A3) non-modified BSA after 10 minutes of incubation. (B) shows the 
relative expression of the relevant phospho-proteins expressed in counts per minute and 
calculated as a ratio to the untreated control cells. 
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4.2.6.3 BSA-AGEs and Non-Modified BSA had Similar Effects on 
Phosphorylation of most of the Protein on KPSS-1.3 Array 
For most of the proteins screened using the phospho-protein array analysis KPSS-1.3. The 
MCF-7 cells exposed to 10 minute-treatment with BSA-AGEs showed same variation of 
phospho-protein expression STAT3, CDK1,ADD3, S4, RB, SAPK, NR and p70S6K1 as 
those analysed after similar treatment with non-modified BSA (Figure 4.9). While BSA-
AGEs and non-modified BSA-treated cells slightly up-regulated the phospho-protein 
expression of the nucleolar nucleocytoplasmic shuttling protein B23, all the other phospho-
proteins were down-regulated and mostly by 50% (Figure4.9). 
 
 
 
 
106 
 
 
Figure 4.9: Effects of BSA-AGEs and non-modified BSA on MCF-7 phospho-protein 
expression from micro-array analysis. (A) Multi-immunoblotting showing the 
expression of 35 phospho-proteins in (A1) untreated MCF-7 cells, (A2) cells treated with 
100 g/mL BSA-AGEs or (A3) non-modified BSA after 10 minutes of incubation. The 
graph (B) shows the relative expression of the relevant phospho-proteins expressed in 
counts per minute and calculated as a ratio to the untreated control cells. Results are 
presented as mean ± SD (n=3). 
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4.2.7 The comparison between the two cell lines: 
The heterogeneity of breast cancer has obliged scientists to use different cell lines, which 
serve as in vitro models to explain the mechanisms involved in its development and 
progression. In this study two main breast cancer cell lines have been used with different 
features in regards to antigenic and expression profiles, tumorigenicity and organ-specific 
metastatic potential (Nagaraja et al, 2006). Despite, the importance of using these different 
breast cancer cell lines, they are not representative of the diversity of the actual tumour. The 
two breast cancer cell lines usually used are MDA-MB231 and MCF-7. The first cell line 
MDA-MB231 was isolated from pleural effusion of a Caucasian breast cancer patient.  
MDA-MB-231 cells are highly invasive, oestrogen-independent and correspond to the late 
stage of breast cancer progression with high aerobic glucose intake rates ( Gupta and Tikoo, 
2013). In contrast to MDA-MB231 cell line, MCF-7 cell line is non-invasive, oestrogen- 
dependent and corresponds to early stage of breast cancer progression. In addition, MCF-7 
cells respond to endocrine therapy with good prognosis. 
This study examined in vitro biological effects of different concentrations of BSA-derived 
AGEs on MDA-MB231 and MCF-7 cell lines compared to non-modified BSA and non- 
treated cells (used as the control). Throughout this study same techniques and conditions 
were applied to both cell lines to establish a comparative study. 
This study demonstrated that BSA-AGEs significantly increase the MDA-MB231 cell 
proliferation, migration, and invasion associated with increased MMP-9 activity and up-
regulate RAGE expression. At the difference of MDA-MB-231 cells, MCF-7 cells exposed 
to BSA-AGEs undergo a slight increase of their proliferation and migration. We also showed 
that MCF-7 cells are unable to invade growth factor-reduced reconstituted basement 
membrane and to produce or activate the gelatinases such as MMP-2 and MMP-9.  The 
significant positive biological effects in both cell lines was observed at 100µg/mL BSA-
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AGEs compared to non-modified BSA and untreated condition (control). The key signalling 
proteins involved in BSA-AGE-mediated cell response were investigated by using the 
phospho-protein array analysis KPSS-1, following 10 minutes treatment of MDA-MB-231 
and MCF-7 with 100 g/mL BSA-AGEs. This phospho-protein array analysis revealed that 
BSA-AGEs enhance expression of ribosomal protein serine S6 kinase beta -1 (p70S6K1) in 
both cell lines BSA-AGEs induce the over-phosphorylation of (p70S6K1) (25.4-fold 
increase) in MDA-MB231 cells compared to the control and non-modified BSA, while in 
MCF-7 cells similar degree of p70S6K1 phosphorylation was observed in BSA-AGE-, non-
modified BSA-treated cells and in untreated cells. The p70S6K1 has a central role in tumour 
growth by regulating pro-angiogenic effects and protein synthesis of insulin (Zhou et al., 
2007; Dennis et al., 2012). Overall, the non-modified BSA has no effect on both cell lines 
except a slight stimulation of MDA-MB231cell proliferation at 50 g/mL and an inhibitory 
effect of MDA-MB231 cell migration at the highest concentration (i.e. 200 g /mL). This 
slight pro-mitogenic effect of non-modified BSA is correlated with the induction of ERK1/2 
phosphorylation observed at short incubation time (10 minutes) at the same concentration 50 
g/mL, whereas no increase in phosphorylation of ERK1/2 was induced by 100 g/mL of 
non-modified BSA. The pro-mitogenic effect of native BSA was also reported by Chung and 
colleagues using tubular epithelial cells in similar conditions. Furthermore, this positive 
effect might possibly be attributed to in vivo derived AGEs from the BSA used. Indeed, BSA 
purchased commercially is found modified by a low degree of glycation that has occurred in 
vivo Indeed, native globular BSA even bound to the cell surface rarely triggers specific 
transduction signalling unlike BSA-AGEs. These signalling investigations clarified the 
greater mitogenic effect of 100 g /mL of BSA-AGEs on MDA-MB-231 cells than on MCF-
7 cells and  identified the impacts of BSA-AGEs on the high production of proteins (revealed 
by concomitant increase of  (p70S6K1) required for increased growth of high invasive breast 
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cancer cells. Additional studies are necessary in order to identify these proteins specifically 
over-produced by these breast cancer cells exposed to BSA-AGEs and involved in cell 
proliferation such as cyclins. Thus, because of heterogeneity between MDA-MB231 and 
MCF-7 cells, it is important to deeper investigate and clarify the molecular mechanisms 
underlying the development of breast cancer contributed by AGEs.  
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Figure 4.10: Micro-array analysis of MDA-MB231 and MCF-7: Effect of BSA-AGEs 
and non-modified BSA on phospho-protein expression in MCF-7 (A) and MDA-MB-231 (B) 
The graphs show the relative expression of the relevant and same phospho-proteins expressed 
in counts per minute and calculated as a ratio to the untreated control cells in both cell lines,. 
Value represents the mean ± SD (n = 3). 
 
 4.3 Discussion 
MCF-7 is a hormone-dependent breast cancer cell line isolated from poorly invasive 
nonmetastatic cells which means that these cells have not developed invasive capacity yet, 
not like MDA-MB-231 cells (Kirschmann et al, 2002). In addition, many studies have 
described differences between MCF-7 and MDA-MB-231cells, in terms of morphology, 
phenotypes and signalling pathways (Kirschmann et al, 2002; Gupta and Tikoo, 2013; 
Mladkova et al, 2010). Therefore, after investigating the effects of BSA-AGEs on MDA-
MB-231 cells, the same studies were applied to MCF-7 cells.  
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First, MCF-7 cells were slow to grow in contrast to MDA-MB-231 due to their sensitivity to 
hormones such as oestrogen and progesterone. Clinically, the suppression of these hormones 
or blocking their receptors is likely to inhibit the development of in situ mammary carcinoma 
(Miller et al, 2011). In this study, MCF-7 cells were treated with different concentrations of 
BSA-AGEs, in comparison to non-modified BSA. Regarding cell migration, the wound-
healing assay used with MDA-MB-231 cells was not applied to MCF-7 cells because these 
latter did not cover the whole surface of the well. Therefore, the effect of BSA-AGEs on 
MCF-7 cells migration was assessed using the Boyden chamber. Like their effects on MDA-
MB-231 cells, non-modified BSA had no effect on MCF-7 migration while BSA-AGEs had 
dose-dependent effects, showing a bell-shaped curve response. BSA-AGEs at the 
concentration of 50 µg/mL and 100 g/mL significantly increased MCF-7 cell growth and 
motility while no effect on cell proliferation and migration were observed when BSA-AGE 
was at 25 g/mL. On the contrary an inhibitory mitogenic effect on MCF-7 cells was noticed 
with 200 g/mL BSA-AGE. This bell-shaped curve observed in response to BSA-AGEs 
suggests the activation of p-ERK1/2 through a receptor whose optimal oligomerization is 
reached in the presence of 50-100 g/mL BSA-AGEs. With regards to their invasive 
capacity, MCF-7 cells treated with BSA-AGE or BSA only for different concentrations as 
expected for a non-metastatic cell line MCF-7, cells were unable to invade growth factor-
reduced reconstituted basement membrane and to produce or activate the gelatinases, MMP-2 
and MMP-9. This finding confirmed previous studies, which also demonstrated the absence 
of gene expression and protein activity of gelatinases in the cells derived from MCF-7 cells 
(Singer et al, 2002). However, other studies have reported MMP-2 production in MCF-7 
cells (Azzam, et al, 1993). These controversies might be explained by the different passages 
or subclones used in their experiments. We also found that 100 g/mL BSA-AGEs induced 
the expression of RAGE in MCF-7 cells, in particular after 24 and 48 hours of incubation. 
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These findings are supported by Tanaka and colleagues (2000) who showed an 
overexpression of RAGE at both mRNA and protein levels following human vascular 
endothelial cell treated with 50 g/mL BSA-AGE for 24 hours, while non-modified BSA had 
no effect (just quick synthesis of RAGE protein at the post-translation level). They also 
identified an AGE- responsive element on RAGE gene, which is the region upstream from 
the transcription start site of RAGE (Tanaka et al, 2000). As previously shown in MDA-MB-
231 in (section 3.4.5), BSA-AGE-induced RAGE up-regulation in MCF-7 cells suggesting a 
positive feedback loop enhancing the cell sensitivity to BSA-AGEs with risk of cancer 
development.One of an important study demonstrated that Glycer-AGEs, significantly 
stimulated the growth and migration of human melanoma cells through their interactions with 
RAGE (Takino et al, 2010). In addition, RAGE interaction with BSA-AGEs enhance pro-
inflammatory and pro-oxidative reactions of the cells, assuming that RAGE might be 
involved in the complication of breast cancer (Yan et al, 1994; Jiao et al, 2011). In addition, 
recently, Lata and Mukherjee (2014) demonstrated the key role of RAGE in the stimulation 
of proliferation and survival of MCF-7 cells induced by a synthetic oestrogen named 17-
ethinyl-estradiol. Altogether, BSA-AGEs might contribute to the growth of the breast cancer 
through stimulation of cancerous cells located in carcinoma in situ with potential synergic 
actions with oestrogen. 
 
An analysis of signalling pathways (mainly involved in cell proliferation) in MCF-7 cells 
following 10 minute treatment with 100 g/mL BSA-AGEs, revealed that BSA-AGEs 
enhanced expression p-ERK1/2, MAPK kinase 1/2 (MKK1/2, an activator of phospho-
ERK1/2) and (CREB1, a well-characterised ERK signalling transcription factor), while 
BSA-AGEs down-regulated the expression of different isoforms of phospho-PKC, (Msk1) 
and phospho-adducin . However, like non-modified BSA, BSA-AGEs had no effect on 
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the phosphorylation of SATAT3, CDK1, ADD3 and S4in MCF-7 cells compared to 
untreated cells. It was previously demonstrated that BSA-AGEs up-regulated phospho-
ERK1/2 expression mainly through RAGE/AGEs axis in MDA-MB-231 cells (section 
3.4.6), BSA-AGEs up-regulate the increase of phospho-ERK1/2 and its upstream activator 
in MKK1/2 by BSA-AGE in MCF-7 cells were not as much as their counter parts in MDA-
MB-231 cells. An increase of MAPK1/2 activity was also reported in rat pulmonary artery 
smooth muscle cells after treatment with 100 g/mL AGE-albumin for 10-15 minutes 
(Lander et al, 1997). The difference in cell signal intensity between MCF-7 and MDA-
MB-231 cells, for example on phospho-ERK1/2 overexpression induced by BSA-AGEs, 
was also observed after chemotherapy with doxorubicin or docetaxel (Taherian and 
Mazoochi, 2012).Thus, the heterogeneity of cell sensitivity to BSA-AGE between MCF-7 
and MDA-MB-231 cells actually reflects the heterogeneity of breast cancers. Furthermore, 
BSA-AGEs up-regulated expression of phospho-CREB1, transcription factor involved in 
cell stress responses, cell survival and proliferation. Recently CREB1 has been 
demonstrated to contribute to malignancy of the breast by inducing transcription of 
aromatase in breast adipose mesenchymal cells, which leads to increased oestrogen levels 
and subsequently to cancer (Chhabra et al, 2007; Samarajeewa et al, 2013). These findings 
suggest that BSA-AGEs might contribute to breast cancer development through activation 
of MAPK pathway and activation of CREB1 transcription factor. On the other hand, in 
present study, BSA-AGEs down-regulated the expression of phospho-PKC, a key signal 
for injury, and phosphor-Msk1, an activated downstream molecule of MAPK signalling. 
The family of PKC, consisting of multiple isoforms, has been associated with enhanced 
activity of transcription factor NF-B, which leads to gene expression encoding pro-
inflammatory cytokines (Ye, 2001). With AGEs, well known as mediators of inflammation 
an increased PKC phosphorylation was expected (Zhang et al, 2011). Many studies have 
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reported PKC activation following RAGE ligation with AGEs in rat cardiomyocytes or 
mesangial cells but so far, not in breast cancer cells (Tuttle et al., 2009; Yu  et al., 2013). 
An increase of Msk1 phosphorylation was expected as MAPK (phospho-ERK1/2) was 
significantly increased (Khan et al., 2013).This surprising finding of down-regulation of 
Msk1 might be due to the level of MAPK activation was not sufficient to subsequently 
activate Msk1. The investigation of signalling pathways present a complex system which 
require additional study and the application of complementary techniques including the 
knock-down of cytoplasmic proteins such as PKC, Msk1 expression or even RAGE 
expression 
In conclusion, we showed for the first time the dose-dependent stimulatory effects of BSA-
AGEs on a hormone-dependent breast cancer cell line MCF-7 cells, with regards cell 
proliferation and directed migration, as compared to non-modified BSA. However, BSA-
AGEs did not change the weak invasive capacity of MCF-7 cells to cross a reconstituted 
basement membrane. In addition, BSA-AGEs induced over-expression of RAGE in MCF-
7 cells. The investigation of signalling pathways suggests that BSA-AGEs might contribute 
to breast cancer development through activation of MAPK pathway and activation of 
CREB1 transcription factor in MCF-7 cells. The knock-down of RAGE expression might 
be a promising targeted therapy to prevent the development of breast cancer in diabetic 
patient.  
0 
 
 
 
 
Chapter 5 
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Chapter 5.1 General Discussion  
This study provides the first evidence that BSA-AGEs promote proliferation, migration 
and invasion of MDA-MB-231 cells probably by modulating MMP-9 activity, up-
regulating RAGE expression and increasing phosphorylation of ERK1/2, STAT-3 and 
p70S6K1, which are involved in cell growth, cell cycle, motility, cell invasion and 
protein synthesis. In contrast to MDA-MB-231 cells, very weak stimulatory effects of 
BSA-AGEs were observed in MCF-7 cells, indicating lower cell sensitivity than MDA-
MB-231 cells to BSA-AGEs. Furthermore, throughout the study, the non-modified BSA 
had negligible effect. 
The morphological and phenotypic heterogeneity of breast cancer have led to the frequent 
use of MDA-MB-231 and MCF-7 cell lines in the determination of bioactivities of 
various compounds, in cytotoxicity measurements, and in studies of specific functions of 
protein and genes after manipulations (Mladkova et al, 2010). Although both cell lines 
are derived from pleural effusions of metastatic mammary carcinoma patients, MDA-
MB-231 is an oestrogen-independent, highly invasive cell line isolated from poor 
prognostic late-stage breast cancer, which corresponds to basal-like subtype accounting 
for 10-17 % of all breast carcinomas (Badve et al, 2011).Whereas MCF-7 is an 
oestrogen-dependent, non-invasive cell line drived from good prognostic early-stage 
breast cancer corresponds to luminal subtype accounting for 60-70% of breast cancinoma 
cases (Blows et al, 2010). Despite the advantages of using these cell lines in cancer 
research, they are not representative of the actual tumour diversity. The differential 
biological effects of BSA-AGEs on MDA-MB-231 and MCF-7 cells demonstrated in 
vitro studies give important molecular insights into the roles of BSA-AGEs in the 
proliferation, migration and invasion of breast cancer cells, which reinforce the link 
between diabetes and breast cancer. In addition, to epidemiological studies which support 
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the pathological consequences of diabetes on the onset and development of cancer 
including breast cancer, a meta-analysis study has reported that breast cancer rates are 
increased by 23% for women who are diagnosed with type 2 diabetes (Liao et al, 2011). 
The use of these two cell lines has allowed us to suggest BSA-AGE-induced p70S6K1 
overexpression in MDA-MB-231 cells as a potential invasive biomarker of breast cancer 
and as a promising therapeutic target to prevent breast cancer development and 
progression in patients diagnosed with diabetes. In addition, the suppression of RAGE 
expression because RAGE play key roles in the pathogenesis of diabetes, and in breast 
cancer development and progression (Ramasamy et al, 2005; Raida et al, 2013). A recent 
study found MDA-MB231 cells expressed higher level of RAGE than MCF-7 cells did 
(Radia et al, 2013).This present study demonstrated that BSA-AGEs induced the 
expression of RAGE in both MDA-MB231 and MCF-7 cell lines. Thus, suppressing 
RAGE expression may be a promising therapeutic method of treating diabetic pateints in 
danger of developing breast cancer and those with over breast cancer. Hence in future, in 
vivo mouse breast cancer models will be of interest to confirm the effects of BSA-AGEs 
on tumour growth and characterization of cancerous epithelial cells which respond to 
BSA-AGEs. This will help to fight against the cancer by targeting and specifically killing 
BSA-AGE stimulated breast cancer cells. 
Despite their phenotypic differences, MDA-MB-231 and MCF-7 cells were cultured in 
similar conditions composed of culture media with normal glucose concentration (5 mM) 
and supplemented with 10% FBS and antibiotics. Although MCF-7 is a hormone-
dependent cell line, the addition of insulin (10 g/mL) in the media impeded cell growth. 
Therefore, the insulin was withdrawn from the culture medium of MCF-7 cells. The use 
of similar culture media (without the addition of insulin) for both MDA-MB-231 and 
MCF-7 cells were also reported in many studies (Mladkova et al, 2010; Gest et al, 2013). 
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In addition, although insulin is considered as a key element for MCF-7 cell growth, a 
recent study has reported that high insulin concentration (25 mM) inhibited MCF-7 cell 
proliferation, whereas MDA-MB-231 cell proliferation was stimulated (Gupta and Tikoo, 
2013). These recent findings support our observation with regards to the withdrawal of 
insulin from the complete medium. The same study demonstrated also the differential 
modulation effect of high glucose concentration (25 mM) on the two breast cancer cell 
lines including a stimulation of MDA-MB-231 cell proliferation with an increased 
phosphorylation of ERK1/2, whereas no change was observed on MCF-7 cell growth 
(Gupta and Tikoo, 2013). A study showed the differences between human breast cancer 
cell lines in susceptibility towards growth inhibition by genistein, a phytoestrogen 
(Dampier et al, 2001). This difference was explained by the different oestrogen receptor 
expression involved including ER- by MDA-MB-231 cells while MCF-7 cells express 
both ER- and ER- receptors (Vladusic et al, 2000; Ford et al, 2011). However, 
surprisingly they showed that genistein induced apoptosis in only MDA-MB-468 cells a 
non-hormone dependenat cell line. In addition, a recent study has reported that in fact 
MDA-MB-231 cells expressed both ER- and ER- receptors (Ford et al, 2011). This 
report published by Ford and colleagues could explain the reason why during cell 
treatment with genistein established by Dampier and colleagues (2001), hormone-
dependent breast cancer cell lines were not distinguished from non-hormone dependent 
breast cancer cell lines. Therefore, despite the different phenotypic characteristics 
between MDA-MB231 and MCF-7 cells, it is essential to use them to identify the impacts 
of BSA-AGEs on the growth and metastatic features of different types of breast cancer 
cells, to investigate their associated heterogeneous spectrums to elucidate possible 
molecular mechanisms underlying the development of breast cancer contributed by 
AGEs.  
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In this study, BSA-AGEs modulated the expression of proteins involved in cell signalling 
pathways differently between in MDA-MB-231 and in MCF-7 cells. MDA-MB-231, 
previously described as a high RAGE expressing cell line (Radia et al, 2013), treated 
with BSA-AGEs had ERK-1/2 MAPK, p38 MAPK, GSK-3, STAT-3 and p70S6K1 
highly over-phosphorylated; whereas MCF-7, previously described as the lowest RAGE 
expression cell line, treated with BSA-AGEs had ERK1/2 and CREB1 (ERK signalling 
transcription factor) had moderately over-phosphorylated and different isoforms (, , , 
/2) of PKC dephosphorylated. These signalling investigations justified the greater 
mitogenic effect of BSA-AGEs on MDA-MB-231 cells than on MCF-7 cells. With 
similar BSA-AGE concentration used (i.e. 100 g/mL), Ishibashi and colleagues (2013) 
have demonstrated that metformin, a chemotherapeutic agent against breast cancer for 
diabetic patients, inhibits BSA-AGE-induced proliferation, VEGF and RAGE expression 
in MCF-7 cells by blocking BSA-AGE-RAGE axis (Ishibashi et al., 2013). A recent 
study demonstrated that inhibition of RAGE using RAGE siRNA in breast cancer cell 
lines down-regulated the expression of transcription factor, NF-B p65 which eventually 
led to the down-regulation of cyclin D1, a protein involved in normal cell cycle 
regulation and responsible for transition from the G1 phase to the S (DNA synthesis) 
phase (Radia et al, 2013). In addition, the expression of these two cytoplasmic proteins 
were also investigated in high glucose-treated MCF-7 and MDA-MB-231 cells (Gupta 
and Tikoo, 2013). High-glucose condition led to a decrease of cyclin D1 expression in 
MCF-7 cells, whereas an increased cyclin D1 expression was observed in MDA-MB-231 
cells (Gupta and Tikoo, 2013). With regards to NF-B expression, an over-
phosphorylation was observed in MCF-7 cells, whereas a de-phosphorylation of NF-B 
was noticed in MDA-MB-231 cells in high glucose condition. They also provided the 
evidence that high glucose promoted carcinogenesis in MDA-MB-231 cells and inhibited 
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cell proliferation in MCF-7 cells. In addition, activation of downstream intracellular 
signalling like MAPK pathway has also been linked to hormone resistance (Tomlinson et 
al, 2012). There is growing evidence that there also exists a cross-communication 
between ER and growth factor receptor signalling such as insulin-like growth factor-1, 
epidermal growth factor (EGF), transforming growth factor (TGF)- and TGF- (Ignar-
Trowbridge et al, 1995; Thorne and Lee, 2003). However, so far, no cross-
communication between ER and RAGE signalling has been described, which opens a 
new door of investigation. 
With regards to MDA-MB-231 cell invasion, here we have shown that BSA-AGEs 
increased MMP-9 activity and not MMP-2. MMP-9 activity in MDA-MB-231 cells was 
also reported by Gest and colleagues (2013) who also demonstrated a decrease in MMP-9 
activity after the knockdown of Rac3, a Rho GTPase with relevant function in cancer 
(Gest et al., 2013). It is known that during breast cancer cell progression, late-stage breast 
cancer cells including MDA-MB-231 cells undergo some changes in the expression 
levels of cathepsin D and other matrix digesting enzymes with loss of ER, with increased 
expression of the mesenchymal marker vimentin and decreased expression of epithelial 
marker E-cadherin, which all are believed to be implicated in breast tumour invasiveness 
(Thompson et al, 1992). Vimentin acquisition has been associated with increased 
metastatic potential through enhanced invasiveness and epithelial-mesenchymal transition 
(Ford et al, 2011). Consequently, an understanding of the underlying causes of tumour 
cell metastasis is essential for the development of new treatments that can slow or arrest 
the progress of breast cancer. Therefore, it will be of interest to assess vimentin 
expression in MDA-MB-231 cells after BSA-AGE treatment. Moreover, this study has 
several limitations such as the difficulties in growing MCF-7 cells in the presence of 
insulin, which impeded the cell growth. Using qRT-PCR to validate AGE induced RAGE 
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expression observed using Westren blotting could be a beneficial step. A further 
limitation of this study was to use only one type of AGE. Future studies are needed to 
evaluate the potential roles of the other AGEs in breast cancer development.  
As aforementioned, the proliferative and invasive abilities of cancer cells, particularly of 
MDA-MB-231 cells, are correlated with aggressiveness and poor clinical prognosis. 
Thus, our present study has improved our understanding of the molecular mechanisms 
involved in the growth and aggressiveness of breast cancer that may be applied for 
identification of new therapeutic targets. 
5.1 Future Studies 
Based on the results of this study, future studies could include: 
- Detect in of highly glycated BSA in the serum of breast cancer patients with 
metastasis. 
- Knock-down of RAGE expression using siRNA technology to confirm the lack of 
activity of RAGE in breast cancer cells, and to measure breast cancer in response to 
therapeutic intervention. 
- In vivo research using animal models carrying different types of breast cancer cells 
which represent the distinctive phenotypic characteristics of MDA-MB231 and MCF-7 
cells to and test the effects of different types of AGEs to identifiy which one play a 
pathogenic role, and which AGE receptors mediate the effects of AGEs on breast 
cancer cells. 
- To address the roles of AGEs in breast cancer and type 2 diabetes by using anti-
glycation methods on animal models and patients who have breast cancer and type 2 
diabetes at the same time.  
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